var title_f11_37_11856="DISH radiographs cervical spine";
var content_f11_37_11856=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F75500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F75500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Cervical spine in diffuse idiopathic skeletal hyperostosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral views of the cervical spine in two individuals with diffuse idiopathic skeletal hyperostosis (DISH). The disc height is well-preserved in both. The individual with more extensive involvement (right panel) complained of mild dysphagia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Esdaile, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_37_11856=[""].join("\n");
var outline_f11_37_11856=null;
var title_f11_37_11857="Destructive arthritis in MCTD";
var content_f11_37_11857=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F62581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F62581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Destructive arthritis in mixed connective tissue disease (MCTD)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Destructive arthritis, including \"telescoping\" of several digits, is a rare complication of mixed connective tissue disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert M Bennett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_37_11857=[""].join("\n");
var outline_f11_37_11857=null;
var title_f11_37_11858="Patient information: Chondromalacia patella (The Basics)";
var content_f11_37_11858=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83795\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/63/6130\">",
"         Chondromalacia patella",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?19/39/20083\">",
"         Patient information: Exercise (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/21/36179\">",
"         Patient information: Giving your child over-the-counter medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/36/7747\">",
"         Patient information: Knee pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/10/18594\">",
"         Patient information: Patellofemoral pain syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/4/24642\">",
"         Patient information: Knee pain (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Chondromalacia patella (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/chondromalacia-patella-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1666784196\">",
"      <span class=\"h1\">",
"       What is chondromalacia patella?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Chondromalacia patella is a condition that causes pain in the front of the knee. It involves the rubbery material, called the &ldquo;cartilage,&rdquo; behind the knee cap (",
"      <a class=\"graphic graphic_figure graphicRef83779 \" href=\"UTD.htm?5/63/6130\">",
"       figure 1",
"      </a>",
"      ). The term doctors use for the knee cap is the &ldquo;patella.&rdquo;",
"     </p>",
"     <p>",
"      Chondromalacia patella describes when the cartilage behind the knee cap gets too soft or wears away.",
"     </p>",
"     <p>",
"      This condition can happen from a knee injury or from bending your knee often.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1666784211\">",
"      <span class=\"h1\">",
"       What are the symptoms of chondromalacia patella?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Chondromalacia patella causes pain in the front of the knee, or around or behind the knee cap.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1666784226\">",
"      <span class=\"h1\">",
"       Is there a test for chondromalacia patella?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your doctor or nurse suspects you have this condition, he or she might order an X-ray or MRI scan of your knee. An MRI scan is an imaging test that creates pictures of the inside of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1666784241\">",
"      <span class=\"h1\">",
"       How is chondromalacia patella treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment for the symptoms caused by chondromalacia patella usually involves a few parts.",
"     </p>",
"     <p>",
"      The first part of treatment helps to reduce your pain. It can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Resting your knee and avoiding activities or movements that make the pain worse",
"       </li>",
"       <li>",
"        Taking nonsteroidal anti-inflammatory drugs, also called &ldquo;NSAIDs&rdquo; &ndash; NSAIDs are a large group of medicines that includes",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;) and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sample brand names: Aleve&reg;, Naprosyn&reg;).",
"       </li>",
"       <li>",
"        Putting ice on your knee when it hurts or after activities that cause pain &ndash; You can put a cold gel pack, bag of ice, or bag of frozen vegetables on the painful area every 1 to 2 hours, for 15 minutes each time. Put a thin towel between the ice (or other cold object) and your skin.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Another part of treatment involves doing exercises to strengthen the muscles around your knee. Your doctor or nurse will show you which exercises to do, or he or she will have you work with a physical therapist (exercise expert).",
"     </p>",
"     <p>",
"      Your doctor might also recommend that you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Wear a knee brace to support your knee.",
"       </li>",
"       <li>",
"        Tape up your knee in a certain way to support your knee.",
"       </li>",
"       <li>",
"        Wear special shoe inserts made to fit your foot (to keep your foot from turning in or out too much).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your symptoms will most likely improve with treatment. But if they don&rsquo;t, your doctor might have you see a knee specialist to discuss treating your condition with surgery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1666784256\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/10/18594?source=see_link\">",
"       Patient information: Patellofemoral pain syndrome (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/36/7747?source=see_link\">",
"       Patient information: Knee pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=see_link\">",
"       Patient information: Exercise (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=see_link\">",
"       Patient information: Giving your child over-the-counter medicines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/4/24642?source=see_link\">",
"       Patient information: Knee pain (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/37/11858?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83795 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-6C4A3AC97D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_37_11858=[""].join("\n");
var outline_f11_37_11858=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1666784196\">",
"      What is chondromalacia patella?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1666784211\">",
"      What are the symptoms of chondromalacia patella?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1666784226\">",
"      Is there a test for chondromalacia patella?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1666784241\">",
"      How is chondromalacia patella treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1666784256\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83795\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/63/6130\">",
"      Chondromalacia patella",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=related_link\">",
"      Patient information: Exercise (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/4/24642?source=related_link\">",
"      Patient information: Knee pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/36/7747?source=related_link\">",
"      Patient information: Knee pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/10/18594?source=related_link\">",
"      Patient information: Patellofemoral pain syndrome (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_37_11859="Uterine morcellation C";
var content_f11_37_11859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 507px\">",
"   <div class=\"ttl\">",
"    Uterine morcellation during vaginal hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 487px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_37_11859=[""].join("\n");
var outline_f11_37_11859=null;
var title_f11_37_11860="Pediatric tachycardia algorithm";
var content_f11_37_11860=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 639px\">",
"   <div class=\"ttl\">",
"    Pediatric tachycardia algorithm (with a pulse and poor perfusion): 2010 PALS guidelines",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 619px; height: 789px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PALS: pediatric advanced life support; IO: intraosseous; IV: intravenous; ECG: electrocardiogram.",
"     <br/>",
"     * Vagal manuevers: In infants or young children, place a plastic bag filled with ice and cold water over the face for 15 to 30 seconds or stimulate the rectum with a thermometer. In older children, encourage bearing down (Valsalva maneuver) for 15 to 20 seconds. Carotid massage and orbital pressure should not be performed in children.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission. Pediatric Advanced Life Support: 2010. American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. &copy; 2010 American Heart Association, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_37_11860=[""].join("\n");
var outline_f11_37_11860=null;
var title_f11_37_11861="Septic embolization PA";
var content_f11_37_11861=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Septic embolization in drug addict with tricuspid valve endocarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 336px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph shows multiple ill-defined nodular opacities, some with cavitation. This is an example of multifocal patchy opacification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_37_11861=[""].join("\n");
var outline_f11_37_11861=null;
var title_f11_37_11862="Leukocytoclastic vasculitits - palpable purpura";
var content_f11_37_11862=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F70300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F70300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Leukocytoclastic vasculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Palpable purpuric lesions are present on the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_37_11862=[""].join("\n");
var outline_f11_37_11862=null;
var title_f11_37_11863="Forearm fascia flap";
var content_f11_37_11863=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F80774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F80774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 608px\">",
"   <div class=\"ttl\">",
"    Radial forearm pedicled tissue transfer flap",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 588px; height: 446px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A radial forearm fascia flap is used for coverage of an electrical injury to the hand. Figure A shows the fascia flap attached to the radial artery. Figure B shows the length of the flap in preparation for coverage of the burned thumb. Figure C shows the pedicled flap covering the burned defect on the thumb.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_37_11863=[""].join("\n");
var outline_f11_37_11863=null;
var title_f11_37_11864="Clomipramine: Pediatric drug information";
var content_f11_37_11864=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clomipramine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"    see \"Clomipramine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/14/26853?source=see_link\">",
"    see \"Clomipramine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F153279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Anafranil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F153280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Anafranil&reg;;",
"     </li>",
"     <li>",
"      Apo-Clomipramine&reg;;",
"     </li>",
"     <li>",
"      CO Clomipramine;",
"     </li>",
"     <li>",
"      Dom-Clomipramine;",
"     </li>",
"     <li>",
"      Novo-Clomipramine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1006546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidepressant, Tricyclic (Tertiary Amine)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1006577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"      see \"Clomipramine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     During initial dose titration, divide the dose and give with meals to minimize nausea and vomiting. During maintenance therapy, may administer total daily dose once daily at bedtime to minimize daytime sedation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"     <b>",
"      Note:",
"     </b>",
"     Controlled clinical trials have not shown tricyclic antidepressants to be superior to placebo for the treatment of depression in children and adolescents (Dopheide, 2006; Wagner, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;10 years: Safety and efficacy have not been established; specific recommendations cannot be made for use in this age group",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;10 years: OCD: Initial: 25 mg/day; gradually increase, as tolerated, to a maximum of 3 mg/kg/day or 100 mg/day (whichever is smaller) during the first 2 weeks; may then gradually increase, if needed, over the next several weeks to a maximum of 3 mg/kg/day or 200 mg/day (whichever is smaller)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: OCD: Initial: 25 mg/day; gradually increase, as tolerated, to 100 mg/day during the first 2 weeks; may then gradually increase, if needed, over the next several weeks to a total of 250 mg/day maximum",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F153259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 25 mg, 50 mg, 75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anafranil&reg;: 25 mg, 50 mg, 75 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F153244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085910.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085910.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5046669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May administer with food to decrease GI upset",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F5978063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Dispense in tightly closed container; protect from moisture.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1006547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of obsessive-compulsive disorder (OCD) (FDA approved in ages &ge;10 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F153332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ClomiPRAMINE may be confused with chlorproMAZINE, clevidipine, clomiPHENE, desipramine, Norpramin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Anafranil&reg; may be confused with alfentanil, enalapril, nafarelin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high [moderate for SIADH]; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F153329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, edema, flushing, orthostatic hypotension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal dreaming, aggressiveness, agitation, anxiety, chills, concentration impaired, confusion, depersonalization,  depression, dizziness, drowsiness, emotional lability, fatigue, fever, headache, hypertonia, insomnia, irritability, malaise, memory impairment,  migraine, nervousness, pain, panic reaction, psychosomatic disorder, somnolence, speech disorder , twitching, yawning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, dermatitis, dry skin, pruritus, purpura, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, breast enlargement, breast pain, hot flashes, hot flushes, lactation (nonpuerperal), libido changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, appetite increased, constipation, diarrhea, dyspepsia, nausea, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria, ejaculation failure, impotence, leukorrhea, micturition disorder, micturition frequency, urinary retention, UTI, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, myalgia, myoclonus, paresis, paresthesia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis, mydriasis, lacrimation abnormal, abnormal vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Coughing, bronchospasm, epistaxis, pharyngitis, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Rare but important or life-threatening: Accommodation abnormal, albuminuria, aneurysm, anticholinergic syndrome, aphasia, apraxia, arrhythmia, ataxia, atrial flutter, blepharitis, blood in stool, bradycardia, breast fibroadenosis, bronchitis, bundle branch block, cardiac arrest, cardiac failure, catalepsy, cellulitis, cerebral hemorrhage, cervical dysplasia, cheilitis, cholinergic syndrome, choreoathetosis, chromatopsia, chronic enteritis, coma, conjunctival hemorrhage, cyanosis, deafness, dehydration, delirium, delusion, diabetes mellitus, diplopia, dyskinesia, dysphonia, dystonia, EEG abnormal, encephalopathy, endometrial hyperplasia, endometriosis, epididymitis, erythematous rash, exophthalmos, extrapyramidal disorder, extrasystoles, gastric ulcer, generalized spasm, glaucoma, glycosuria, goiter, gynecomastia, hallucinations, heart block, hematuria, hemiparesis, hemoptysis, hepatitis, hostility, hyperacusis, hypercholesterolemia, hyper-/hypoesthesia, hyperglycemia, hyper-/hypokinesia, hyper-reflexia, hyper-/hypothyroidism, hyperuricemia, hyper-/hypoventilation, hypnagogic hallucination, hypokalemia, ideation, intestinal obstruction, irritable bowel syndrome, keratitis, laryngismus, leukemoid reaction, lupus erythematosus rash, lymphadenopathy, lymphoma-like disorder, maculopapular rash, manic reaction, marrow depression, myocardial infarction, myocardial ischemia, myopathy, myositis, neuralgia, neuropathy, oculogyric crisis, oculomotor nerve paralysis, oral/pharyngeal edema, ovarian cyst, paralytic ileus, paranoia, parosmia, peptic ulcer, peripheral ischemia, phobic disorder, photophobia, photosensitivity reaction, pneumonia, polyarteritis nodosa, premature ejaculation, psychosis, pyelonephritis, pyuria, rectal hemorrhage, renal calculus, renal cyst, schizophrenic reaction, scleritis, seizure, sensory disturbance, skin ulceration, strabismus, stupor, suicidal ideation, suicide, suicide attempt, thrombophlebitis, tongue ulceration, torticollis, urinary incontinence, uterine hemorrhage, uterine inflammation, vaginal hemorrhage, vasospasm, ventricular tachycardia, visual field defect, withdrawal syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1006554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clomipramine, other tricyclic agents, or any component; use of MAO inhibitors within 14 days (potentially fatal reactions may occur); use in a patient during the acute recovery phase of MI",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F4092850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause sedation, resulting in impaired performance of tasks requiring alertness (eg, operating machinery or driving). Sedative effects may be additive with other CNS depressants and/or ethanol. The degree of sedation is very high relative to other antidepressants. Vomiting is two- to threefold more prevalent in children compared to adolescents and is more prevalent in adolescents compared to adults; to help minimize, divide the dose and give with food initially. Once titrated to maintenance therapy, can consolidate to once daily dosing at bedtime. Weight gain may occur. May increase the risks associated with electroconvulsive therapy; limit such treatment to patients in whom it is essential. Consider discontinuing, when possible, prior to elective surgery. Therapy should not be abruptly discontinued in patients receiving high doses for prolonged periods.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May cause tachycardia and orthostatic hypotension (risk is moderate to high relative to other antidepressants); use with caution in patients at risk of hypotension or in patients where transient tachycardia and hypotensive episodes would be poorly tolerated (cardiovascular disease or cerebrovascular disease). The degree of anticholinergic blockade produced by this agent is very high relative to other cyclic antidepressants; use with caution in patients with urinary retention, benign prostatic hyperplasia, narrow-angle glaucoma, increased IOP, xerostomia, visual problems, constipation, or history of bowel obstruction. Upon abrupt discontinuation, the effects of cholinergic rebound (eg, nausea, vomiting, diarrhea, salivation, lacrimation) may be more problematic in youth compared to adults. It is unknown what (if any) effects that long-term clomipramine treatment may have on growth and development in children.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Use with caution in patients with a history of cardiovascular disease (including previous MI, stroke, tachycardia, or conduction abnormalities). The risk of conduction abnormalities with this agent is high relative to other antidepressants. Use with caution in hyperthyroid patients or those receiving thyroid supplementation. Use with caution in patients with tumors of the adrenal medulla (hypertensive crisis may result). Use with caution in patients with hepatic or renal dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1006555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Clinical worsening of depression or suicidal ideation and behavior may occur in children and adults with major depressive disorder",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . In clinical trials, antidepressants increased the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (18-24 years of age) with major depressive disorder and other psychiatric disorders. This risk must be considered before prescribing antidepressants for any clinical use. Short-term studies did not show an increased risk of suicidality with antidepressant use in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Patients of all ages who are treated with antidepressants for any indication require appropriate monitoring and close observation for clinical worsening of depression, suicidality, and unusual changes in behavior, especially during the first few months after antidepressant initiation or when the dose is adjusted. Family members and caregivers should be instructed to closely observe the patient (ie, daily) and communicate condition with healthcare provider. Patients should also be monitored for associated behaviors (eg, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania) which may increase the risk for worsening depression or suicidality. Worsening depression or emergence of suicidality (or associated behaviors listed above) that is abrupt in onset, severe, or not part of the presenting symptoms, may require discontinuation or modification of drug therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Do not discontinue abruptly in patients receiving high doses chronically (withdrawal symptoms may occur). To reduce risk of intentional overdose, write prescriptions for the smallest quantity consistent with good patient care. Screen individuals for bipolar disorder prior to treatment (using antidepressants alone may induce manic episodes in patients with this condition). May worsen psychosis in some patients. Clomipramine is not FDA approved for the treatment of bipolar depression.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Clomipramine may cause seizures (direct relationship to dose and/or duration of therapy); do not exceed maximum doses. Use with caution in patients with a previous seizure disorder or condition predisposing to seizures such as brain damage, alcoholism, or concurrent therapy with other drugs which lower the seizure threshold.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F153317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2C19 (major), CYP2D6 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F153253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Tricyclic Antidepressants may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Tricyclic Antidepressants may enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: Tricyclic Antidepressants may diminish the antihypertensive effect of Alpha2-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Tricyclic Antidepressants may enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Tricyclic Antidepressants may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the serum concentration of ClomiPRAMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DULoxetine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of ClomiPRAMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Tricyclic Antidepressants may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neurotoxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Tricyclic Antidepressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Milnacipran: ClomiPRAMINE may enhance the adverse/toxic effect of Milnacipran. Specifically, the incidence of euphoria and postural hypotension were higher in patients changing from clomipramine to milnacipran. ClomiPRAMINE may enhance the serotonergic effect of Milnacipran. This could result in serotonin syndrome.  Management: Coadminister with caution.  Monitor more closely for euphoria, postural hypotension, serotonin toxicity/serotonin syndrome, and other adverse events when switching from clomipramine to milnacipran or if these drugs are to be used in combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of CYP2D6 Inhibitors (Moderate).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Tricyclic Antidepressants may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure and/or loss of consciousness may be increased in patients with significant sodium phosphate induced fluid/electrolyte abnormalities.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Tricyclic Antidepressants. The risk of serotonin syndrome may theoretically be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Cyclic Antidepressants may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terbinafine (Systemic): May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tricyclic Antidepressants may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: Tricyclic Antidepressants may increase the serum concentration of Yohimbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5046668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food does not affect bioavailability. Grapefruit juice may increase serum concentrations or toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F153254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F153268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Withdrawal symptoms (including jitteriness, tremor, and seizures) have been observed in neonates whose mothers took clomipramine up to delivery.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1006581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor patient periodically for symptom resolution; monitor for worsening depression, suicidality, and associated behaviors (especially at the beginning of therapy or when doses are increased or decreased).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Monitor weight, pulse rate and blood pressure prior to and during therapy; ECG and cardiac status in patients with cardiac disease; periodic liver enzymes in patients with liver disease;  CBC with differential in patients who develop fever and sore throat during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1006571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tricyclic antidepressants increase the synaptic concentration of serotonin and/or norepinephrine in the CNS by inhibition of their reuptake by the presynaptic neuronal membrane. Clomipramine appears to affect serotonin uptake while its active metabolite, desmethylclomipramine, affects norepinephrine uptake.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F4092851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Onset of action: 1-2 weeks",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Maximum effect: 8-12 weeks",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Duration: 1-2 days",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1006573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes into CSF, brain, and breast milk; active metabolite (desmethylclomipramine) also distributes into CSF with average CSF to plasma ratio: 2.6",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 97%; primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to desmethylclomipramine (DMI; active) and other metabolites; extensive first-pass effect; metabolites undergo glucuronide conjugation; metabolism of clomipramine and DMI may be capacity limited (ie, may display nonlinear pharmacokinetics); with multiple dosing, plasma concentrations of DMI are greater than clomipramine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults (following a 150 mg dose): Clomipramine 19-37 hours (mean: 32 hours); DMI: 54-77 hours (mean: 69 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 50% to 60% of dose is excreted in the urine and 24% to 32% in feces; only 0.8% to 1.3% is excreted in urine as parent drug and active metabolite (combined amount)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1006585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/14/26853?source=see_link\">",
"      see \"Clomipramine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide that you receive with each prescription and refill of clomipramine. An increased risk of suicidal thinking and behavior has been reported with the use of antidepressants in children, adolescents, and young adults (18-24 years of age). Notify physician if you feel more depressed, have thoughts of suicide, or become more agitated or irritable. Avoid alcohol, grapefruit juice, and the herbal medicine St John's wort; limit caffeine intake. This medication may cause drowsiness, lightheadedness, impaired coordination, dizziness, or blurred vision and impair ability to perform activities requiring mental alertness or physical coordination. May cause dry mouth or unpleasant aftertaste (sucking lozenges and frequent mouth care may help). Do not discontinue abruptly (withdrawal symptoms may occur).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     If multiple doses are prescribed per day, take with meals to reduce side effects. Take single daily dose at bedtime to reduce daytime sedation. Do not take any new medication during therapy unless approved by prescriber. Take exactly as directed; do not increase dose or frequency; may take 2-3 weeks to achieve desired results. May cause headache, seizures, constipation, or orthostatic hypotension (use caution when rising from lying or sitting to standing position or when climbing stairs). Report unresolved constipation or GI upset, blurred vision or eye pain, difficulty in urination, unusual muscle weakness, chest pain, palpitations, rapid heart beat, or persistent CNS disturbances (hallucinations, suicidality, seizures, delirium, insomnia, or impaired gait).",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F5046670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If used for an extended period of time, long-term usefulness of clomipramine should be periodically re-evaluated for the individual patient.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Braconnier A, LeCoent R, Cohen D, et al, \"Paroxetine Versus Clomipramine in Adolescents With Severe Major Depression: A Double-Blind, Randomized, Multicenter Trial,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2003, 42(1):22-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/37/11864/abstract-text/12500073/pubmed\" id=\"12500073\" target=\"_blank\">",
"        12500073",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cano-Munoz JL, Montejo-Iglesias ML, Yanez-Saez RM, et al, &ldquo;Possible Serotonin Syndrome Following the Combined Administration of Clomipramine and Alprazolam,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1995, 56(3):122.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/37/11864/abstract-text/7883731/pubmed\" id=\"7883731\" target=\"_blank\">",
"        7883731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dale O and Hole A, &ldquo;Biphasic Time-Course of Serum Concentrations of Clomipramine and Desmethylclomipramine After a Near-Fatal Overdose,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1994, 36(4):309-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/37/11864/abstract-text/7975135/pubmed\" id=\"7975135\" target=\"_blank\">",
"        7975135",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dopheide JA, \"Recognizing and Treating Depression in Children and Adolescents,\"",
"      <i>",
"       Am J  Health Syst Pharm",
"      </i>",
"      , 2006, 63(3):233-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/37/11864/abstract-text/16434782/pubmed\" id=\"16434782\" target=\"_blank\">",
"        16434782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Geller DA, \"Obsessive Compulsive and Spectrum Disorders in Children and Adolescents,\"",
"      <i>",
"       Psychiatr Clin North Am",
"      </i>",
"      , 2006, 29(2):353-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/37/11864/abstract-text/16650713/pubmed\" id=\"16650713\" target=\"_blank\">",
"        16650713",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hernandez AF, Montero MN, Pla A, et al, &ldquo;Fatal Moclobemide Overdose or Death Caused by Serotonin Syndrome?&rdquo;",
"      <i>",
"       J Forensic Sci",
"      </i>",
"      , 1995, 40(1):128-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/37/11864/abstract-text/7876795/pubmed\" id=\"7876795\" target=\"_blank\">",
"        7876795",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kuisma MJ, &ldquo;Fatal Serotonin Syndrome With Trismus,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1995, 26(1):108.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/37/11864/abstract-text/7793712/pubmed\" id=\"7793712\" target=\"_blank\">",
"        7793712",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larochelle P, Hamet P, and Enjalbert M, &ldquo;Responses to Tyramine and Norepinephrine After Imipramine and Trazodone,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1979, 26(1):24-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/37/11864/abstract-text/376211/pubmed\" id=\"376211\" target=\"_blank\">",
"        376211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larrey D, Rueff B, Pessayre D, et al, &ldquo;Cross Hepatotoxicity Between Tricyclic Antidepressants,&rdquo;",
"      <i>",
"       Gut",
"      </i>",
"      , 1986, 27(6):726-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/37/11864/abstract-text/3721296/pubmed\" id=\"3721296\" target=\"_blank\">",
"        3721296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lejoyeux M, et al, &ldquo;Serotonin Syndrome: Incidence, Symptoms, and Treatment,&rdquo;",
"      <i>",
"       CNS Drugs",
"      </i>",
"      , 1994, 2:132-43.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ljungren B and Bojs G, &ldquo;A Case of Photosensitivity and Contact Allergy to Systemic Tricyclic Drugs, With Unusual Features,&rdquo;",
"      <i>",
"       Contact Dermatitis",
"      </i>",
"      , 1991, 24(4):259-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/37/11864/abstract-text/1831106/pubmed\" id=\"1831106\" target=\"_blank\">",
"        1831106",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/37/11864/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roberge RJ, Martin TG, Hodgman M, et al, &ldquo;Acute Chemical Pancreatitis Associated With a Tricyclic Antidepressant (Clomipramine) Overdose,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1994, 32(4):425-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/37/11864/abstract-text/8057402/pubmed\" id=\"8057402\" target=\"_blank\">",
"        8057402",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Safer DJ and Zito JM, &ldquo;Treatment-Emergent Adverse Events From Selective Serotonin Reuptake Inhibitors by Age Group: Children vs Adolescents,&rdquo;",
"      <i>",
"       J Child and Adolesc Psychopharmacol",
"      </i>",
"      , 2006, 16(1/2):159-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/37/11864/abstract-text/16553536/pubmed\" id=\"16553536\" target=\"_blank\">",
"        16553536",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sternbach H, &ldquo;Fluoxetine-Clomipramine Interaction,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1995, 56(4):171-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/37/11864/abstract-text/7713858/pubmed\" id=\"7713858\" target=\"_blank\">",
"        7713858",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Svedmyr N, &ldquo;The Influence of a Tricyclic Antidepressive Agent (Protriptyline) on Some of the Circulatory Effects of Noradrenaline and Adrenalin&reg; in Man,&rdquo;",
"      <i>",
"       Life Sci",
"      </i>",
"      , 1968, 7(1):77-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/37/11864/abstract-text/5636628/pubmed\" id=\"5636628\" target=\"_blank\">",
"        5636628",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Swanson-Biearman B, Goetz CM, Dean BS, et al, &ldquo;Anafranil&reg; Overdose: A Fatal Outcome,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1989, 31:378.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tueth MJ, &ldquo;The Serotonin Syndrome in the Emergency Department,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1993, 22(8):1369.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/37/11864/abstract-text/8333648/pubmed\" id=\"8333648\" target=\"_blank\">",
"        8333648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagner KD, \"Pharmacotherapy for Major Depression in Children and Adolescents,\"",
"      <i>",
"       Prog Neuropsychopharmacol Biol Psychiatry",
"      </i>",
"      , 2005, 29(5):819-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/37/11864/abstract-text/15908090/pubmed\" id=\"15908090\" target=\"_blank\">",
"        15908090",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walsh KH and McDougle CJ, \"Pharmacological Strategies for Trichotillomania,\"",
"      <i>",
"       Expert Opin  Pharmacother",
"      </i>",
"      , 2005, 6(6):975-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/37/11864/abstract-text/15952925/pubmed\" id=\"15952925\" target=\"_blank\">",
"        15952925",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13050 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_37_11864=[""].join("\n");
var outline_f11_37_11864=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708676\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153279\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153280\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006546\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006577\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153259\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153244\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874420\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5046669\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5978063\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006547\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153332\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153329\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006554\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4092850\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006555\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153317\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153253\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5046668\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153254\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153268\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006581\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006571\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4092851\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006573\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006585\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5046670\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13050\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13050|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=related_link\">",
"      Clomipramine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/14/26853?source=related_link\">",
"      Clomipramine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_37_11865="Surgical valve replacement in aortic stenosis in adults";
var content_f11_37_11865=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical valve replacement in aortic stenosis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/37/11865/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/37/11865/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/37/11865/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/37/11865/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/37/11865/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/37/11865/contributors\">",
"     Edward Verrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/37/11865/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/37/11865/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/37/11865/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic valve replacement is the only established treatment for symptomatic severe aortic stenosis (AS). When correction of AS is warranted (",
"    <a class=\"graphic graphic_table graphicRef68344 \" href=\"UTD.htm?29/2/29740\">",
"     table 1",
"    </a>",
"    ), there are several surgical considerations that must be addressed: the possibility of aortic valve repair, the use of a mechanical valve, and the use of a variety of bioprosthetic valves, including stented aortic valves, stentless aortic valves, aortic homografts, the Ross procedure, and the use of biological aortic root prostheses. In patients who are considered inoperable, transcatheter aortic valve replacement (TAVR) is a potential option.",
"   </p>",
"   <p>",
"    Surgical valve replacement will be reviewed here. The indications for aortic valve replacement including risk assessment, percutaneous aortic valvotomy, TAVR, and issues relating to the medical management of asymptomatic AS and to valve disease in elderly adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link\">",
"     \"Indications for valve replacement in aortic stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/5/7252?source=see_link\">",
"     \"Estimating the mortality risk of valvular surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39411?source=see_link\">",
"     \"Percutaneous aortic valvotomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/29/34264?source=see_link\">",
"     \"Transcatheter aortic valve replacement\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2025?source=see_link\">",
"     \"Medical management of asymptomatic aortic stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34377?source=see_link\">",
"     \"Valvular heart disease in elderly adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHOICE OF VALVE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanical versus bioprosthetic valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the Society of Thoracic Surgeons show that among patients undergoing isolated aortic valve replacement (mostly for AS) in the United States in 2006, 20.6 percent received a mechanical valve, 78.4 percent a bioprosthetic valve, and 0.1 percent a homograft [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both mechanical and bioprosthetic valves have been used for aortic valve replacement (AVR). Issues to consider when choosing the appropriate valve include [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mechanical valves are more durable [",
"      <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mechanical valves require lifelong anticoagulation.",
"     </li>",
"     <li>",
"      Some biological aortic valve options are technically more challenging than others (Ross procedure &gt; aortic homografts &gt; stentless AVR &gt; stented AVR)",
"     </li>",
"     <li>",
"      Stented tissue valves are associated with smaller effective orifice areas (EOA), due to the space occupied by the supporting stents. This can be particularly important in patients with a small aortic annulus who are a risk for patient-prosthesis mismatch [",
"      <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Prosthetic valve-patient mismatch'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Tissue valves have a low risk for thromboembolism, and do not require lifelong anticoagulation.",
"     </li>",
"     <li>",
"      Although observations have varied, infection generally occurs with equal frequency on mechanical and bioprosthetic devices during the first postoperative year. Bioprosthetic valves carry a greater risk for infection than mechanical valves after the first 18 months. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/40/2697?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reoperations after certain biological valves (eg, homographs) are technically more challenging than after implantation of standard bioprosthetic valves.",
"   </p>",
"   <p>",
"    The greater durability of mechanical valves was illustrated in a Veterans Affairs trial in which 394 patients undergoing single AVR were randomly assigned to receive a bioprosthetic (Hancock porcine) or mechanical valve (Bjork-Shiley spherical disc prosthesis) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/4\">",
"     4",
"    </a>",
"    ]. After a 15 year follow-up, the mechanical valve was associated with the following significant benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reduction in all-cause mortality, which was valve-related in approximately 40 percent of patients (66 versus 79 percent for the bioprosthesis).",
"     </li>",
"     <li>",
"      Primary valve failure occurred only with the bioprosthetic valve (26 versus 0 percent for mechanical valve) in patients less than 65 years of age and 9 versus 0 percent in those &ge;65 years of age (9 versus 0 percent).",
"     </li>",
"     <li>",
"      A lower incidence of reoperation (10 versus 29 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There was no statistical difference in the incidence of other complications with the two types of valves, including endocarditis, thromboembolism, or valve thrombosis. Another study found no difference in quality of life at 18 months between patients receiving mechanical or bioprosthetic valves [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link&amp;anchor=H3#H3\">",
"     \"Complications of prosthetic heart valves\", section on 'Mechanical versus bioprosthetic valves'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link&amp;anchor=H5#H5\">",
"     \"Complications of prosthetic heart valves\", section on 'Structural failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Major society guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    and the 2007 European Society of Cardiology (ESC) guidelines for the management of valvular heart disease guidelines made the following general recommendations for the choice of aortic valve, recognizing that patient preference may also play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A mechanical valve is recommended in patients who already have a mechanical valve in the mitral or tricuspid position (and therefore already need anticoagulation).",
"     </li>",
"     <li>",
"      A mechanical valve is reasonable (a weaker recommendation) in patients under 65 years of age who do not have a contraindication to anticoagulation.",
"     </li>",
"     <li>",
"      A bioprosthesis is recommended in patients of any age who will not take or have major contraindications to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy.",
"     </li>",
"     <li>",
"      A bioprosthesis is reasonable in patients &ge;65 years of age who do not have risk factors for thromboembolism and in patients under age 65 who choose this approach for lifestyle reasons after a detailed review of the risks of anticoagulation compared to the greater likelihood of a second valve surgery in the future.",
"     </li>",
"     <li>",
"      Valve re-replacement with a homograft is reasonable in patients with active prosthetic valve endocarditis.",
"     </li>",
"     <li>",
"      The evidence was considered less well established for a bioprosthesis in women of childbearing age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, a mechanical valve may be recommended for patients with small aortic roots in whom annular enlargement is high risk or contraindicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Patients &lt;65 years of age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of concerns about limited valve durability as well as higher long-term mortality rates in patients receiving bioprosthetic rather than mechanical valves in the Veterans Affairs trial, the above guidelines favor implantation of mechanical valves among patients &lt;65 years of age who do not have a contraindication to anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/2,7\">",
"     2,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a study published after the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    and 2007 ESC guidelines suggests that long-term mortality is not higher among patients &lt;60 years old receiving an initial bioprosthetic rather than mechanical valve, despite higher rates of valve reoperation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/8\">",
"     8",
"    </a>",
"    ]. The study analyzed &ge;20 year follow-up data from 567 patients who were &lt;60 years old at the time of initial aortic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mitral valve replacement. There was no long-term survival difference between patients implanted with a bioprosthetic versus mechanical prosthesis at initial aortic valve replacement (25 year survival rates of 52 versus 41 percent, hazard ratio 0.95). As expected 20-year follow-up revealed a significantly higher rate of valve reoperation with a bioprosthetic valve (89 versus 27 percent).",
"   </p>",
"   <p>",
"    Given the similar survival with both valve types, these findings emphasize that valve choice in adults &lt;60 years of age should take patient preferences into account, specifically regarding the likelihood of repeat valve surgery versus need for long term anticoagulation. A detailed and balanced discussion of the issues is vital for informed consent.",
"   </p>",
"   <p>",
"    A major limitation of both this study and the Veterans Affairs trial is that majority of valves studied are not in current use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Elderly patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a particular preference for a bioprosthetic valve in elderly patients, which is based in part upon the observation that the longevity of these valves is inversely related to age [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/4,9,10\">",
"     4,9,10",
"    </a>",
"    ]. In one report, the actuarial estimate of the rate of structural deterioration of bioprosthetic aortic valves at 15 years varied from 63 percent between the ages of 40 and 49 (and perhaps higher under age 40) to 10 percent over age 70 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/9\">",
"     9",
"    </a>",
"    ]. Similar findings were noted in the Veterans Affairs trial in which the rate of valve failure at 15 years varied from 26 percent under age 65 to 9 percent in patients &ge;65 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lower rate of valve failure in elderly adults is due at least in part to decreased activity in older patients. The net effect is that the life expectancy of an octogenarian is shorter than the expected functional life of a bioprosthesis.",
"   </p>",
"   <p>",
"    In a review of aortic valve replacement in 1100 patients &ge;80 years of age, a bioprosthetic valve was implanted in 88 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/11\">",
"     11",
"    </a>",
"    ]. A similar frequency of bioprosthetic valve use (81 percent) was reported in a series of 2447 patients &ge;65 years of age who underwent aortic valve replacement between 1992 and 2004 at the Brigham and Women's Hospital in Boston [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the strong rationale for bioprosthetic valves in elderly adults, national practice in the United States is quite different. This was illustrated in a review of over 80,000 patients &ge;65 years of age who underwent isolated aortic valve replacement at more than 1000 hospitals between 1999 and 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/13\">",
"     13",
"    </a>",
"    ]. Only 52 percent received a bioprosthetic valve, including only 60 percent in patients over age 90. The authors highlighted a correlation between low hospital valve surgery volume and more frequent use of mechanical valves. Bioprosthetic valves were used in only 28 percent of cases at hospitals in the lowest volume decile compared to 68 percent in the highest volume decile. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34377?source=see_link&amp;anchor=H2#H2\">",
"     \"Valvular heart disease in elderly adults\", section on 'Aortic stenosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The guidelines made no specific recommendations on the choice of valve in patients with AS who have end-stage renal disease. There appears to be no significant difference in outcomes with mechanical and bioprosthetic valves. Although it may be more difficult to maintain anticoagulation in these patients when a mechanical valve is implanted, accelerated valve calcification is likely with a tissue prosthesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/59/954?source=see_link&amp;anchor=H20#H20\">",
"     \"Valvular heart disease in patients with end-stage renal disease\", section on 'Aortic stenosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Pre-existing coronary artery bypass grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The morbidity and mortality associated with valve reoperation may be higher in some patient populations, such as those with coronary artery bypass grafts. Retrospective data indicate that operative mortality rates are high for aortic valve replacement with pre-existing coronary artery bypass grafts (and higher than for combined aortic valve and bypass graft surgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In the presence of a patent internal mammary artery (IMA) graft, aortic valve surgery poses a potential risk of IMA graft injury and myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/16\">",
"     16",
"    </a>",
"    ]. The increased risk associated with valve reoperation should be considered in choosing a valve for a patient with coronary artery bypass grafts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Potential impact of new developments",
"    </span>",
"    &nbsp;&mdash;&nbsp;One challenge in choosing a prosthetic valve is that long-term outcomes data are not available for the newest prosthetic valves and operative techniques. Advances in cardiac surgery and perioperative care may reduce the risk of valve reoperation. Comparisons of bioprosthetic valve series suggest that second generation porcine valves and pericardial valves are more durable than first generation porcine valves; newer models may yield even greater durability but data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Types of bioprosthetic valves'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Types of mechanical heart valves",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major types of mechanical heart valves in current use are [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Caged ball valves, predominantly the Starr-Edwards ball-in-cage prosthesis which was first FDA approved in 1965. The Starr-Edwards valve is highly durable but has unfavorable hemodynamic properties, particularly in smaller sizes, and may pose greater thromboembolic risk than other valve types. Implantation of this valve declined sharply since the 1980s.",
"     </li>",
"     <li>",
"      Bileaflet prosthetic valves, predominantly the St. Jude valve FDA approved in 1977 and the Carbomedics valve approved in 1993. Others include the ATS open pivot valve approved in 2000 and the On-X valve approved in 2001.",
"     </li>",
"     <li>",
"      Tilting disc valves, predominantly the Medtronic-Hall (previously Hall-Kaster) single tilting disc valve FDA approved in 1977 and the Omniscience valve approved in 1978. Others include the Monostrut valve approved in 1997.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Bjork-Shiley convexo-concave (BSCC) single tilting disc valve was FDA approved in 1979 but withdrawn from the market in 1986 after reports of outlet strut fractures. This complication is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link&amp;anchor=H7#H7\">",
"     \"Complications of prosthetic heart valves\", section on 'BSCC valve'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The four mechanical heart valves with the largest implant records are the Starr-Edwards ball-in-cage valve (rare since the 1980s), the Medtronic-Hall single tilting disc valve, the St. Jude bileaflet valve, and the Carbomedics bileaflet valve [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/19\">",
"     19",
"    </a>",
"    ]. Limited retrospective data on the last three valves suggest no definite difference in outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/18,20,21\">",
"     18,20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial compared clinical outcomes following St Jude versus Carbomedics aortic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mitral valve replacement in 485 patients (288 aortic valve only replacements) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/22\">",
"     22",
"    </a>",
"    ]. No significant differences were observed in 10-year rates of survival (65 and 66 percent, respectively) or freedom from valve-related complications (46 and 52 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Types of bioprosthetic valves",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two types of stented bioprosthetic aortic valves: porcine valves, and pericardial prostheses. There are at least three types of stentless biological valves: porcine, bovine, and equine, in addition to aortic homografts and human allografts (Ross).",
"   </p>",
"   <p>",
"    Among patients who receive a bioprosthesis, both pericardial and porcine prostheses have very similar durability data. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 531 aortic porcine prostheses, the actuarial freedom from reoperation at five and ten years was 95 and 83 percent, respectively, for aortic valves [",
"      <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a comparable series of 598 aortic pericardial prostheses, the values were 97 and 91 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a single center of experience with both types of valves in the aortic position, the 10-year freedom from reoperation was higher with pericardial than porcine aortic valves (97 versus 90 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, all of these figures represent projected outcomes for patient populations with a mean actual follow-up duration of five to six years. Thus, longer experience is needed to definitively assess the comparative durability of these valves [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among porcine valves, it has been proposed that stentless valves, although more complicated to implant, are associated with a larger effective orifice area, which might lead to more complete regression of left ventricular hypertrophy and, therefore, improved long-term outcomes.",
"   </p>",
"   <p>",
"    This issue was directly assessed in the ASSERT trial in which 190 patients undergoing aortic valve replacement for severe AS were randomly assigned to a stentless or stented porcine valve [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/27\">",
"     27",
"    </a>",
"    ]. Despite a greater increase in effective orifice area and lower transvalvular velocities with the stentless valve, there was no difference between the groups in the rate of reduction in left ventricular mass or clinical outcomes. Equivalent outcomes with stentless and stented values were also noted in another randomized trial of 160 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A separate potential benefit of stentless valves is increased durability. A multicenter study of 725 patients receiving stentless aortic valves reported high rates of freedom from structural valve deterioration at 12 years (92 percent for patients aged &le;60 and &gt;60 years old). However, the study reported no stented valve group for comparison [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/17\">",
"     17",
"    </a>",
"    ]. Some concern has been raised that when stentless valves deteriorate, the process may be more acute than the chronic deterioration commonly seen with stented biological prostheses.",
"   </p>",
"   <p>",
"    Homograft aortic valves are most often used for treatment of endocarditis because the homograft is supplied as a composite valve, aortic root, and part of the anterior mitral leaflet. This additional tissue may be used to reconstruct the areas adjacent to the valve, which can be of particular value if the infection has extended into the annulus, basal septum, or base of the mitral valve. Otherwise, homografts do not have any specific advantages, compared to other tissue valves, in terms of durability or resistance to infection.",
"   </p>",
"   <p>",
"    A disadvantage of homograft valves is that fibrosis (involving the adjacent pulmonary artery) and calcification (frequently involving the coronary button reattachment) of the composite root and valve makes it more difficult to perform repeat surgical intervention, which often is needed on long term follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prosthetic valve-patient mismatch",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prosthetic valve-patient mismatch (PPM) is considered to be present when the effective orifice area (EOA) indexed for body surface area is less than that of a normal human valve [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/29\">",
"     29",
"    </a>",
"    ]. PPM is considered not clinically significant if the indexed EOA is &gt;0.85",
"    <span class=\"nowrap\">",
"     cm2/m2,",
"    </span>",
"    moderate if &gt;0.65 to &le;0.85",
"    <span class=\"nowrap\">",
"     cm2/m2,",
"    </span>",
"    and severe if &le;0.65",
"    <span class=\"nowrap\">",
"     cm2/m2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/30\">",
"     30",
"    </a>",
"    ]. The main clinical concern is the presence of a high transvalvular gradient through a normally functioning valve.",
"   </p>",
"   <p>",
"    PPM appears to be more likely with bioprosthetic valves. This was illustrated in a review of 1400 consecutive patients who underwent bioprosthetic or mechanical aortic valve replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/31\">",
"     31",
"    </a>",
"    ]. PPM, defined as an EOA &lt;0.75",
"    <span class=\"nowrap\">",
"     cm2/m2,",
"    </span>",
"    was present in 51 percent of patients with bioprosthetic valves compared with 11 percent in those with mechanical valves.",
"   </p>",
"   <p>",
"    PPM is associated with adverse early- and long-term outcomes. However, multivariate analyses of long-term outcomes have yielded conflicting results. PPM was an independent predictor of risk of late mortality in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/32-34\">",
"     32-34",
"    </a>",
"    ], but not in others [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. As an example of the variable findings, a study of 3343 patients undergoing aortic valve replacement with mean 6.2 year follow-up found that survival was significantly worse among those with severe PPM as compared to those with no PPM (22.1 percent versus 38.1 percent at 15 years), but was not an independent predictor of mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential explanations for discrepancies among studies in the impact of PPM on outcomes include differing criteria for PPM as well as a variety of clinical factors that may influence the effect of PPM on outcomes. These factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age &mdash; Severe PPM was associated with increased mortality in younger patients (&lt;60 or &lt;70 years old) but not in older patients in two series [",
"      <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/31,37\">",
"       31,37",
"      </a>",
"      ]. A potential contributing factor is that younger patients are more active, which leads to higher stroke volumes and therefore higher transvalvular gradients.",
"     </li>",
"     <li>",
"      Obesity and body size &mdash; In a series of 2576 patients, severe PPM was associated with mortality in patients with BMI &lt;30",
"      <span class=\"nowrap\">",
"       kg/m2,",
"      </span>",
"      but had no impact in obese patients [",
"      <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/37\">",
"       37",
"      </a>",
"      ]. One potential explanation for the lack of apparent impact of PPM in large patients may be that indexed EOA (EOA divided by BSA) may overestimate the degree of mismatch in these patients. In another report of 1400 patients, moderate PPM was not important in small patients (BSA &lt;1.7 m2) but was associated with mortality among average-sized patients (body surface area, BSA 1.7 to 2.1 m2) with either bioprosthetic or mechanical valves and among large patients (BSA &gt;2.1 m2) with mechanical valves [",
"      <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduced left ventricular ejection fraction &mdash; The presence of left ventricular systolic dysfunction (LVEF &lt;40 or 50 percent) appears to confer susceptibility to adverse early and late outcomes in patients with PPM [",
"      <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/30,37,38\">",
"       30,37,38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given these observations, every effort should be made to minimize the likelihood of severe PPM. Protocols have been suggested to attain this goal in which the EOA at rest should at least 0.85 to 0.90",
"    <span class=\"nowrap\">",
"     cm2/m2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/29\">",
"     29",
"    </a>",
"    ]. One approach for patients with relatively small aortic roots is aortic root enlargement which, in one series, lowered the rate of moderate to severe PPM from 17 to 2.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/39\">",
"     39",
"    </a>",
"    ]. An alternative approach is use of a stentless valve root conduit as noted above. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Types of bioprosthetic valves'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Among patients who have severe mismatch, reoperation may be required with the same indications as those for native valve stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/29,33\">",
"     29,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pulmonary autograft (Ross procedure)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Ross procedure is an alternative to valve replacement with a mechanical valve or bioprosthesis. It involves replacing the aortic valve with a pulmonic valve autograft and right-sided reconstruction with an aortic or pulmonary homograft [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Use of the Ross procedure has been limited because of its technical complexity, complications with both the aortic autograft and the pulmonic homograft, and the availability of simpler and effective alternatives, ie, mechanical valves and bioprostheses including stentless bioprosthetic valves.",
"   </p>",
"   <p>",
"    There are a number of potential advantages of the Ross procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Autologous tissue with documented long-term viability",
"     </li>",
"     <li>",
"      Optimal hemodynamic data",
"     </li>",
"     <li>",
"      Regeneration capacity",
"     </li>",
"     <li>",
"      Possible resistance to infection (eg, 0.2 to 0.3",
"      <span class=\"nowrap\">",
"       percent/patient",
"      </span>",
"      year [",
"      <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/43,44\">",
"       43,44",
"      </a>",
"      ] as compared to &gt;0.4",
"      <span class=\"nowrap\">",
"       percent/patient",
"      </span>",
"      year for recipients of prosthetic valves) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/40/2697?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Lack of valve noise",
"     </li>",
"     <li>",
"      Freedom from anticoagulation due to rates of thromboembolic complications ranging from 0 to up to 1.2 percent per year",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Strong relative contraindications to the Ross procedure include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Advanced three vessel coronary disease",
"     </li>",
"     <li>",
"      Other extensive valve pathology requiring replacement",
"     </li>",
"     <li>",
"      Severely depressed left ventricular function",
"     </li>",
"     <li>",
"      Multisystem organ failure",
"     </li>",
"     <li>",
"      Pulmonary valve pathology",
"     </li>",
"     <li>",
"      Marfan syndrome or other connective tissue disorders",
"     </li>",
"     <li>",
"      Size mismatch between the pulmonic and aortic annulus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Ross procedure has been used most successfully in children and adolescents, but has also been performed in adults less than 50 years of age with single valve pathology, mechanical or bioprosthetic valve failure, endocarditis limited to the aortic root, and athletes or young patients in whom anticoagulation is contraindicated and for whom optimal hemodynamics are desired (eg, a female of reproductive age). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27032?source=see_link\">",
"     \"Pregnancy in women with a bicuspid aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pulmonary autograft in the aortic position provides excellent hemodynamics at rest and with maximum exercise; however, there may be a moderately high gradient across the homograft in the pulmonary valve position [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of studies have noted good short term results with the Ross procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/46-51\">",
"     46-51",
"    </a>",
"    ]. In a meta-analysis of 39 reports published from 2000 to 2008, the pooled early mortality rates for consecutive adult and pediatric series, adult series and pediatric series were 3.0, 3.2 and 4.2 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/51\">",
"     51",
"    </a>",
"    ]. However early mortality rates varied from 0.3 to 6.8 percent even among these selected centers.",
"   </p>",
"   <p>",
"    Selected older patients may do well with this approach, at least in the short to intermediate term. The experience with the Ross procedure was reviewed in a series of 27 patients more than 60 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/49\">",
"     49",
"    </a>",
"    ]. After a mean follow-up of 28 months, there was no mortality and only one patient required autograft replacement. When compared to 84 younger patients (mean age 44) who underwent the Ross procedure, there were no differences in hemodynamic variables for either autografts or homografts except for a slightly higher pressure gradient across the pulmonary homograft in the older patients.",
"   </p>",
"   <p>",
"    Good intermediate to long term results have been reported in various pediatric and adult series. In a meta-analysis of 39 reports with one to 8.7 year follow-up, the pooled late mortality rates for consecutive adult and pediatric series, adult series and pediatric series were 0.48, 0.64 and 0.62 percent per year, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/51\">",
"     51",
"    </a>",
"    ]. In adult series, the autograft deterioration rate was 0.78 percent per year and the right ventricular outflow conduit deterioration rate was 0.55 percent per year.",
"   </p>",
"   <p>",
"    Longer term results suggest a high risk of reoperation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/43,44,48\">",
"     43,44,48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At 20 years after operation in the pioneering series of 131 patients (age 11 to 52), survival was 61 percent, freedom from autograft reoperation was 75 percent, and freedom from pulmonary homograft reoperation was 80 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/48\">",
"       48",
"      </a>",
"      ]. The mortality rate increased age.",
"     </li>",
"     <li>",
"      At 16 years after operation in a series of 487 patients (age 2 days to 62 years), actuarial survival was 82 percent, freedom from autograft failure (reoperation and valve-related death) was 74 percent, and freedom from pulmonary allograft reoperation was 80 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/44\">",
"       44",
"      </a>",
"      ]. Actuarial freed om from valve-related morbidity (includes autograft and pulmonary allograft failure, endocarditis, and valve-related death) was 63 percent at 16 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Current use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of the Ross procedure in adults is controversial and the procedure is only performed at a few experienced centers. There may be more perioperative complications since the surgery is longer and more complicated than simple aortic valve replacement. Dilation of the pulmonic autograft with autograft failure is a significant late complication [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/43,44,48,52\">",
"     43,44,48,52",
"    </a>",
"    ] associated with surgical technique in some series [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/53\">",
"     53",
"    </a>",
"    ] but not others [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/44,50\">",
"     44,50",
"    </a>",
"    ]. Since patients with preoperative aortic regurgitation and dilated aortic annulus are at risk for future dilation and failure of the pulmonary autograft [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/44\">",
"     44",
"    </a>",
"    ], some recommend avoidance of the Ross procedure in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/54\">",
"     54",
"    </a>",
"    ]. The pulmonary homograft is also prone to stenosis, sometimes early after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even at experienced centers, use of this procedure has waned since the 1990s. Reasons include the postoperative prevalence of annular dilatation with aortic regurgitation, the long-term reoperation rate of 20 percent or more, and the availability of alternative stentless valve root conduit options.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     VALVE AND AORTIC ROOT REPLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A bicuspid aortic valve is a common cause of AS requiring valve replacement in all age groups [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11865/abstract/56\">",
"     56",
"    </a>",
"    ]. In such patients, there is the additional concern about proximal aortic abnormalities and dilatation, which can lead to aneurysm formation or dissection. Monitoring and indications for concomitant aortic root replacement are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7078?source=see_link\">",
"     \"Treatment of bicuspid aortic valve stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MINIMALLY INVASIVE SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of minimally invasive aortic valve surgery in patients with AS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/38/30310?source=see_link\">",
"     \"Minimally invasive aortic and mitral valve surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Catheter based aortic valve implantation is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39411?source=see_link\">",
"     \"Percutaneous aortic valvotomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/53/36690?source=see_link\">",
"       \"Patient information: Aortic stenosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30754100\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aortic valve replacement is the only established treatment of symptomatic severe aortic stenosis (AS). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Choice of valve is determined by considerations, including the greater durability but requirement of lifelong anticoagulation with mechanical valves. Anticoagulation is not required for bioprosthetic valves but the risk of valve failure is greater with associated risk of reoperation. Some bioprosthetic valves are more challenging to implant. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanical versus bioprosthetic valve'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Thus, implantation of a mechanical valve is generally preferred in patients &lt;65 years of age who do not have a contraindication to anticoagulation.",
"     </li>",
"     <li>",
"      Implantation of a bioprosthetic valve is generally preferred in patients with life expectancy less than the expected functional life of a bioprosthesis. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A limitation of long-term valve studies is that they generally provide data on valve types which are not currently being implanted. Newer types of bioprosthetic valves may be more durable than previously studied types but data are insufficient to determine this. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Potential impact of new developments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Types of mechanical heart valves include bileaflet prosthetic valves and tilting disc valves as well as the older caged ball valves. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Types of mechanical heart valves'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Types of bioprosthetic heart valves include stented valves (porcine and pericardial), stentless valves (porcine, bovine, and equine), as well as aortic homografts and human allografts (Ross procedure). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Types of bioprosthetic valves'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prosthetic valve-patient mismatch (PPM) was an independent predictor of mortality in some studies, but not in others. Since it can cause clinically significant obstruction, every effort should be made to minimize the likelihood of severe PPM. Strategies for patients with small aortic roots include aortic root enlargement or use of a stentless valve root conduit. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Prosthetic valve-patient mismatch'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Ross procedure involves replacing the aortic valve with a pulmonic valve autograft and right-sided reconstruction with an aortic or pulmonary homograft. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Pulmonary autograft (Ross procedure)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of the Ross procedure in adults has declined due to risk of postoperative annular dilatation with aortic regurgitation, long-term reoperation rate of 20 percent or more, and the availability of alternative stentless valve root conduit options. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Current use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with bicuspid aortic valve are at risk for aortic root and ascending aorta dilatation and dissection. Indications for concomitant aortic valve and aortic root replacement are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7078?source=see_link\">",
"       \"Treatment of bicuspid aortic valve stenosis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Use of minimally invasive aortic valve surgery in patients with AS is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/38/30310?source=see_link\">",
"       \"Minimally invasive aortic and mitral valve surgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Catheter based aortic valve implantation is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39411?source=see_link\">",
"       \"Percutaneous aortic valvotomy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/29/34264?source=see_link\">",
"       \"Transcatheter aortic valve replacement\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/1\">",
"      Brown JM, O'Brien SM, Wu C, et al. Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons National Database. J Thorac Cardiovasc Surg 2009; 137:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/2\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/3\">",
"      Bloomfield P, Wheatley DJ, Prescott RJ, Miller HC. Twelve-year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses. N Engl J Med 1991; 324:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/4\">",
"      Hammermeister K, Sethi GK, Henderson WG, et al. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol 2000; 36:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/5\">",
"      Botzenhardt F, Eichinger WB, Bleiziffer S, et al. Hemodynamic comparison of bioprostheses for complete supra-annular position in patients with small aortic annulus. J Am Coll Cardiol 2005; 45:2054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/6\">",
"      Sedrakyan A, Hebert P, Vaccarino V, et al. Quality of life after aortic valve replacement with tissue and mechanical implants. J Thorac Cardiovasc Surg 2004; 128:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/7\">",
"      Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/8\">",
"      Ruel M, Chan V, B&eacute;dard P, et al. Very long-term survival implications of heart valve replacement with tissue versus mechanical prostheses in adults &lt;60 years of age. Circulation 2007; 116:I294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/9\">",
"      Yun KL, Miller DC, Moore KA, et al. Durability of the Hancock MO bioprosthesis compared with standard aortic valve bioprostheses. Ann Thorac Surg 1995; 60:S221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/10\">",
"      Rahimtoola SH. Choice of prosthetic heart valve for adult patients. J Am Coll Cardiol 2003; 41:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/11\">",
"      Asimakopoulos G, Edwards MB, Taylor KM. Aortic valve replacement in patients 80 years of age and older: survival and cause of death based on 1100 cases: collective results from the UK Heart Valve Registry. Circulation 1997; 96:3403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/12\">",
"      Cohn LH. Use of heart valves in older patients. Circulation 2005; 111:2152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/13\">",
"      Schelbert EB, Vaughan-Sarrazin MS, Welke KF, Rosenthal GE. Hospital volume and selection of valve type in older patients undergoing aortic valve replacement surgery in the United States. Circulation 2005; 111:2178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/14\">",
"      Verhoye JP, Merlicco F, Sami IM, et al. Aortic valve replacement for aortic stenosis after previous coronary artery bypass grafting: could early reoperation be prevented? J Heart Valve Dis 2006; 15:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/15\">",
"      Smith WT 4th, Ferguson TB Jr, Ryan T, et al. Should coronary artery bypass graft surgery patients with mild or moderate aortic stenosis undergo concomitant aortic valve replacement? A decision analysis approach to the surgical dilemma. J Am Coll Cardiol 2004; 44:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/16\">",
"      Byrne JG, Karavas AN, Filsoufi F, et al. Aortic valve surgery after previous coronary artery bypass grafting with functioning internal mammary artery grafts. Ann Thorac Surg 2002; 73:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/17\">",
"      Bach DS, Metras J, Doty JR, et al. Freedom from structural valve deterioration among patients aged &lt; or = 60 years undergoing Freestyle stentless aortic valve replacement. J Heart Valve Dis 2007; 16:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/18\">",
"      Akins CW. Results with mechanical cardiac valvular prostheses. Ann Thorac Surg 1995; 60:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/19\">",
"      Gott VL, Alejo DE, Cameron DE. Mechanical heart valves: 50 years of evolution. Ann Thorac Surg 2003; 76:S2230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/20\">",
"      Masters RG, Helou J, Pipe AL, Keon WJ. Comparative clinical outcomes with St. Jude Medical, Medtronic Hall and CarboMedics mechanical heart valves. J Heart Valve Dis 2001; 10:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/21\">",
"      Anttila V, Heikkinen J, Biancari F, et al. A retrospective comparative study of aortic valve replacement with St. Jude medical and medtronic-hall prostheses: a 20-year follow-up study. Scand Cardiovasc J 2002; 36:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/22\">",
"      Bryan AJ, Rogers CA, Bayliss K, et al. Prospective randomized comparison of CarboMedics and St. Jude Medical bileaflet mechanical heart valve prostheses: ten-year follow-up. J Thorac Cardiovasc Surg 2007; 133:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/23\">",
"      Glower DD, Landolfo KP, Cheruvu S, et al. Determinants of 15-year outcome with 1,119 standard Carpentier-Edwards porcine valves. Ann Thorac Surg 1998; 66:S44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/24\">",
"      Poirer NC, Pelletier LC, Pellerin M, Carrier M. 15-year experience with the Carpentier-Edwards pericardial bioprosthesis. Ann Thorac Surg 1998; 66:S57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/25\">",
"      Gao G, Wu Y, Grunkemeier GL, et al. Durability of pericardial versus porcine aortic valves. J Am Coll Cardiol 2004; 44:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/26\">",
"      Jamieson SW, Madani MM. The choice of valve protheses. J Am Coll Cardiol 2004; 44:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/27\">",
"      Perez de Arenaza D, Lees B, Flather M, et al. Randomized comparison of stentless versus stented valves for aortic stenosis: effects on left ventricular mass. Circulation 2005; 112:2696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/28\">",
"      Chambers JB, Rimington HM, Hodson F, et al. The subcoronary Toronto stentless versus supra-annular Perimount stented replacement aortic valve: early clinical and hemodynamic results of a randomized comparison in 160 patients. J Thorac Cardiovasc Surg 2006; 131:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/29\">",
"      Pibarot P, Dumesnil JG. Hemodynamic and clinical impact of prosthesis-patient mismatch in the aortic valve position and its prevention. J Am Coll Cardiol 2000; 36:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/30\">",
"      Blais C, Dumesnil JG, Baillot R, et al. Impact of valve prosthesis-patient mismatch on short-term mortality after aortic valve replacement. Circulation 2003; 108:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/31\">",
"      Moon MR, Pasque MK, Munfakh NA, et al. Prosthesis-patient mismatch after aortic valve replacement: impact of age and body size on late survival. Ann Thorac Surg 2006; 81:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/32\">",
"      Blackstone EH, Cosgrove DM, Jamieson WR, et al. Prosthesis size and long-term survival after aortic valve replacement. J Thorac Cardiovasc Surg 2003; 126:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/33\">",
"      Mohty D, Mohty-Echahidi D, Malouf JF, et al. Impact of prosthesis-patient mismatch on long-term survival in patients with small St Jude Medical mechanical prostheses in the aortic position. Circulation 2006; 113:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/34\">",
"      Tasca G, Mhagna Z, Perotti S, et al. Impact of prosthesis-patient mismatch on cardiac events and midterm mortality after aortic valve replacement in patients with pure aortic stenosis. Circulation 2006; 113:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/35\">",
"      Taggart DP. Prosthesis patient mismatch in aortic valve replacement: possible but pertinent? Eur Heart J 2006; 27:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/36\">",
"      Jamieson WR, Ye J, Higgins J, et al. Effect of prosthesis-patient mismatch on long-term survival with aortic valve replacement: assessment to 15 years. Ann Thorac Surg 2010; 89:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/37\">",
"      Mohty D, Dumesnil JG, Echahidi N, et al. Impact of prosthesis-patient mismatch on long-term survival after aortic valve replacement: influence of age, obesity, and left ventricular dysfunction. J Am Coll Cardiol 2009; 53:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/38\">",
"      Ruel M, Al-Faleh H, Kulik A, et al. Prosthesis-patient mismatch after aortic valve replacement predominantly affects patients with preexisting left ventricular dysfunction: effect on survival, freedom from heart failure, and left ventricular mass regression. J Thorac Cardiovasc Surg 2006; 131:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/39\">",
"      Castro LJ, Arcidi JM Jr, Fisher AL, Gaudiani VA. Routine enlargement of the small aortic root: a preventive strategy to minimize mismatch. Ann Thorac Surg 2002; 74:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/40\">",
"      Ross DN. Replacement of aortic and mitral valves with a pulmonary autograft. Lancet 1967; 2:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/41\">",
"      Ross D, Jackson M, Davies J. The pulmonary autograft--a permanent aortic valve. Eur J Cardiothorac Surg 1992; 6:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/42\">",
"      Oury JH. Clinical aspects of the Ross procedure: indications and contraindications. Semin Thorac Cardiovasc Surg 1996; 8:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/43\">",
"      Klieverik LM, Takkenberg JJ, Bekkers JA, et al. The Ross operation: a Trojan horse? Eur Heart J 2007; 28:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/44\">",
"      Elkins RC, Thompson DM, Lane MM, et al. Ross operation: 16-year experience. J Thorac Cardiovasc Surg 2008; 136:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/45\">",
"      Pibarot P, Dumesnil JG, Briand M, et al. Hemodynamic performance during maximum exercise in adult patients with the ross operation and comparison with normal controls and patients with aortic bioprostheses. Am J Cardiol 2000; 86:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/46\">",
"      Oury JH, Hiro SP, Maxwell JM, et al. The Ross Procedure: current registry results. Ann Thorac Surg 1998; 66:S162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/47\">",
"      Matsuki O, Okita Y, Almeida RS, et al. Two decades' experience with aortic valve replacement with pulmonary autograft. J Thorac Cardiovasc Surg 1988; 95:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/48\">",
"      Chambers JC, Somerville J, Stone S, Ross DN. Pulmonary autograft procedure for aortic valve disease: long-term results of the pioneer series. Circulation 1997; 96:2206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/49\">",
"      Schmidtke C, Bechtel JF, Noetzold A, Sievers HH. Up to seven years of experience with the Ross procedure in patients &gt;60 years of age. J Am Coll Cardiol 2000; 36:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/50\">",
"      Hanke T, Stierle U, Boehm JO, et al. Autograft regurgitation and aortic root dimensions after the Ross procedure: the German Ross Registry experience. Circulation 2007; 116:I251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/51\">",
"      Takkenberg JJ, Klieverik LM, Schoof PH, et al. The Ross procedure: a systematic review and meta-analysis. Circulation 2009; 119:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/52\">",
"      Kouchoukos NT, Masetti P, Nickerson NJ, et al. The Ross procedure: long-term clinical and echocardiographic follow-up. Ann Thorac Surg 2004; 78:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/53\">",
"      David TE, Omran A, Ivanov J, et al. Dilation of the pulmonary autograft after the Ross procedure. J Thorac Cardiovasc Surg 2000; 119:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/54\">",
"      Takkenberg JJ, Klieverik LM, Schoof PH, et al. The Ross procedure: a systematic review and meta-analysis. Circulation 2009; 119:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/55\">",
"      Concha M, Aranda PJ, Casares J, et al. Prospective evaluation of aortic valve replacement in young adults and middle-aged patients: mechanical prosthesis versus pulmonary autograft. J Heart Valve Dis 2005; 14:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11865/abstract/56\">",
"      Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation 2005; 111:920.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8143 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-B63444C5D6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_37_11865=[""].join("\n");
var outline_f11_37_11865=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30754100\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHOICE OF VALVE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanical versus bioprosthetic valve",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Major society guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Patients &lt;65 years of age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Elderly patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Pre-existing coronary artery bypass grafts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Potential impact of new developments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Types of mechanical heart valves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Types of bioprosthetic valves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prosthetic valve-patient mismatch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pulmonary autograft (Ross procedure)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Current use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      VALVE AND AORTIC ROOT REPLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MINIMALLY INVASIVE SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30754100\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8143\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8143|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/2/29740\" title=\"table 1\">",
"      ACC AHA AVR in aortic stenosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=related_link\">",
"      Complications of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/40/2697?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/5/7252?source=related_link\">",
"      Estimating the mortality risk of valvular surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=related_link\">",
"      Indications for valve replacement in aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2025?source=related_link\">",
"      Medical management of asymptomatic aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/38/30310?source=related_link\">",
"      Minimally invasive aortic and mitral valve surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/53/36690?source=related_link\">",
"      Patient information: Aortic stenosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39411?source=related_link\">",
"      Percutaneous aortic valvotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27032?source=related_link\">",
"      Pregnancy in women with a bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/29/34264?source=related_link\">",
"      Transcatheter aortic valve replacement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7078?source=related_link\">",
"      Treatment of bicuspid aortic valve stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34377?source=related_link\">",
"      Valvular heart disease in elderly adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/59/954?source=related_link\">",
"      Valvular heart disease in patients with end-stage renal disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_37_11866="Treatment of locally advanced unresectable or recurrent rectal cancer";
var content_f11_37_11866=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of locally advanced unresectable or recurrent rectal cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/37/11866/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/37/11866/contributors\">",
"     Christopher G Willett, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/37/11866/contributors\">",
"     Miguel A Rodriguez-Bigas, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/37/11866/contributors\">",
"     David P Ryan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/37/11866/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/37/11866/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/37/11866/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/37/11866/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/37/11866/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 40,340 Americans are diagnosed with rectal cancer annually [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/1\">",
"     1",
"    </a>",
"    ]. Surgical resection is the cornerstone of curative therapy for patients with early stage, potentially resectable disease. The addition of radiation therapy (RT) and chemotherapy can enhance both local control and cure rates in patients with either transmural invasion or positive perirectal lymph nodes.",
"   </p>",
"   <p>",
"    Such therapy is often administered preoperatively. While the only definitive indication for preoperative chemoradiotherapy is the presence of a T3 or T4 (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ) rectal cancer, other relative indications include a",
"    <span class=\"nowrap\">",
"     T1/2",
"    </span>",
"    lesion that is clinically node-positive, a distal tumor for which tumor regression may allow successful conversion of a planned APR to a sphincter-sparing surgical procedure, or if the preoperative staging evaluation suggests the presence of mesorectal invasion. While most of these patients are technically resectable at presentation, outcomes are better with preoperative chemoradiotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link&amp;anchor=H2#H2\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\", section on 'Indications for neoadjuvant treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Definition of locally advanced disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with rectal cancer present with more locally advanced or recurrent but nonmetastatic disease that cannot be easily resected. The criteria for unresectability are variable and not clearly defined. Some define a locally advanced tumor as one with endorectal ultrasound evidence of a",
"    <span class=\"nowrap\">",
"     T3/4",
"    </span>",
"    or N1 tumor, or one that is",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clinically bulky [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our view, a good working definition of a locally advanced rectal tumor is one that, in the assessment of the multidisciplinary management team of surgeons, radiation and medical oncologists, radiologists, and gastroenterologists, cannot be resected without a high likelihood of leaving microscopic or gross residual disease at the local site because of tumor adherence or fixation. A locally advanced lesion can range from a tethered or marginally resectable tumor to a fixed cancer that directly invades adjacent critical structures (eg, the duodenum, pelvic side wall).",
"   </p>",
"   <p>",
"    The definition of locally advanced disease also depends upon whether the assessment of resectability is made clinically or intraoperatively. In some cases, a tumor that is considered unresectable by clinical or radiographic examination may be amenable to curative resection when the patient is examined under anesthesia.",
"   </p>",
"   <p>",
"    In the past, management of these patients has been variable. Since they do poorly with surgery alone, combined modality treatment programs have evolved that incorporate RT, chemotherapy, and surgery. The multimodality approach to the patient with locally advanced or locally recurrent nonmetastatic rectal cancer will be reviewed here. Preoperative (neoadjuvant) chemoradiotherapy and postoperative adjuvant therapy for earlier stage mobile rectal cancer, surgical principles, and recommendations for posttreatment surveillance are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4922?source=see_link\">",
"     \"Adjuvant therapy for resected rectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6041?source=see_link\">",
"     \"Pretreatment local staging evaluation for rectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28634?source=see_link\">",
"     \"Surveillance after colorectal cancer resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The designation of locally advanced rectal cancer generally rests upon physical examination and radiographic studies such as CT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    magnetic resonance imaging (MRI).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Physical and endoscopic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Digital rectal examination (DRE) and rigid sigmoidoscopy are essential to the surgical decision-making process. On DRE, fixation of the lesion to the anal sphincter, its relationship to the anorectal ring (the collection of muscles that make up the sphincters), and fixation to both the rectal wall and the pelvic wall muscles (levators) can be assessed. Sigmoidoscopy can accurately determine the distance between the distal tumor margin, the top of the anorectal ring, and the dentate line.",
"   </p>",
"   <p>",
"    Adequate clinical assessment of local tumor extension may require an examination under anesthesia. In some cases, a tumor that is considered unresectable by clinical or radiographic examination may be amenable to curative resection when the patient is examined under anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;While preoperative imaging is imperative in planning the surgical procedure, imaging is imperfect, and it can underestimate the extent of adjacent organ involvement. CT, in particular, can accurately identify locoregionally confined disease and the need for adjacent organ resection, but it is less helpful in predicting local tumor resectability [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/3\">",
"     3",
"    </a>",
"    ]. CT is more useful for assessing the presence of distant metastatic spread. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17946?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations, diagnosis, and staging of colorectal cancer\", section on 'Clinical staging evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thin cut MRI with pelvic phased-array coil is the preferred imaging modality in evaluating the extent of the primary tumor as it will be able to provide information on the circumferential margin as well as invasion to other organs and structures. Endorectal ultrasound may be limited by the bulkiness of the tumor and the lack of depth to assess invasion to other organs. MRI exceeds the capability of CT scan to locally stage the depth of transmural invasion, presence or absence of invasion into adjacent structures, and the presence of perirectal nodal involvement for rectal cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. As an example, in a study of 26 patients with locoregionally advanced rectal cancer, the sensitivity of MRI for identifying infiltration of adjacent structures was 97 percent compared to only 70 percent for CT [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/4\">",
"     4",
"    </a>",
"    ]. MRI correctly predicted all four cases of sacral bone invasion, three of which were missed by CT.",
"   </p>",
"   <p>",
"    The utility of endorectal MRI and endorectal ultrasound for staging rectal cancer is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6041?source=see_link&amp;anchor=H5#H5\">",
"     \"Pretreatment local staging evaluation for rectal cancer\", section on 'Imaging evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to a digital clinical examination (which may require an examination under anesthesia) and rigid sigmoidoscopy, the preoperative evaluation should include both CT and either rectal MRI or transrectal ultrasound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GENERAL SURGICAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Practice guidelines from the National Comprehensive Cancer Network (NCCN), the National Cancer Institute, and the American Society of Colon and Rectal Surgeons, as well as quality performance indicators for colorectal cancer surgery developed by an independent group, emphasize that appropriate surgical management of locally advanced, adherent rectal cancers (ie, T4 disease) (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ) should include multivisceral resection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. Compared with standard resection, multivisceral resection is associated with better local control and survival [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/11-17\">",
"     11-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In practice, preoperative chemoradiotherapy is generally favored over upfront surgery for patients with T4 disease (see below) As long as there has been a good clinical response, as assessed intraoperatively, multivisceral resection may not be needed unless the tumor is adhered to other structures.",
"   </p>",
"   <p>",
"    When needed, en bloc resections of adjacent organs or structures that are adherent to the tumor should be accomplished. Given that the risk of histologically proven malignant adhesions is between 40 to 84 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/7\">",
"     7",
"    </a>",
"    ], separating the adhesions between the tumor and other structures should be avoided as this will increase the risk for local recurrence and decrease survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Exenterative procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total pelvic exenteration and its modifications are surgical options for the treatment of locally advanced or recurrent rectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/18\">",
"     18",
"    </a>",
"    ]. A total pelvic exenteration involves the removal of the rectum, anus, lower ureters, urinary bladder, and the uterus, ovaries and vagina in females; the prostate is removed in males. A modified exenteration can be either anterior, posterior, or supralevator:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anterior exenterations leave the rectum in place while the bladder and internal reproductive organs are removed.",
"     </li>",
"     <li>",
"      A posterior pelvic exenteration (PPE) involves removal of the rectum, anus, uterus, ovaries, and posterior vaginal wall.",
"     </li>",
"     <li>",
"      A supralevator exenteration is one in which a sphincter saving procedure can be performed. It could be a PPE where a primary colorectal anastomosis is performed, or an en bloc removal of the bladder, or uterus and ovaries and posterior vaginal wall, and rectum where a primary colorectal anastomosis is performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Composite resections are exenterative procedures whereby the en bloc resection includes resection of bony structures such as the sacrum and coccyx.",
"   </p>",
"   <p>",
"    Continence-sparing surgery may be possible as long as sound oncologic surgical principles are followed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/19\">",
"     19",
"    </a>",
"    ]. In general, if exenterative surgery is considered, it should be undertaken as one component of a multimodality plan incorporating radiation and chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In primary locally advanced rectal cancer, reported rates of five-year overall survival after exenterative surgery are between 43 to 54 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/18\">",
"     18",
"    </a>",
"    ]. In another review of 24 patients with locally advanced or recurrent rectal cancer, the five-year overall survival was 44 percent overall and 64 percent in those with primary locally advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Historically, these major procedures carried a high morbidity and mortality, with a substantial negative impact on long-term quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. More recent series report perioperative morbidity rates between 47 and 61 percent, with approximately 20 to 30 percent of these requiring reoperation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. Perioperative mortality after exenterative surgery has also decreased over time. In specialized centers, the mortality rates are less than 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT OF LOCALLY ADVANCED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of locally advanced or clinical stage T4 (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ) rectal cancer has evolved. At present, most patients with locally advanced unresectable but nonmetastatic rectal cancer are treated with combined modality therapy, including preoperative chemoradiotherapy, surgery and postoperative chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     RT alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with locally advanced disease, primary curative-intent external beam RT results in high local failure rates and a five year survival &lt;10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Thus, unless the patient is not a candidate for surgery, RT alone has",
"    <strong>",
"     no role",
"    </strong>",
"    as definitive treatment, but it is an essential component of multimodality treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     External beam RT and surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 1980s, treatment programs of moderate to high dose RT followed by surgery showed that a complete resection was possible in one-half to two-thirds of patients with locally advanced rectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. However, local failure occurred in at least one-third of these patients. RT has been administered either postoperatively or preoperatively, alone or with chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Postoperative RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who have undergone incomplete resection of a locally advanced rectal cancer, the addition of postoperative (adjuvant) RT improves local control and survival in patients who have residual microscopic disease; it is less effective in those with gross residual disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. RT should not be expected to compensate for an inadequate surgical procedure.",
"   </p>",
"   <p>",
"    This can be illustrated by a report in which 31 resected patients with microscopic residual disease were treated with 45 Gy followed by additional RT up to 60 to 70 Gy if the small bowel could be moved from the radiation treatment volume [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/34\">",
"     34",
"    </a>",
"    ]. Five year local control and disease-free survival rates were 70 and 45 percent, respectively. In contrast, the respective values were 43 and 11 percent for the 25 patients who had gross residual disease after attempted resection, and local control was not improved by higher RT doses in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Preoperative RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients presenting with locally advanced and particularly for fixed rectal cancers, preoperative conventional fractionation RT (45 to 50 Gy in 5.5 to 6 weeks) can reduce tumor size and facilitate resection. The rate of resectability following such an approach is 39 to 65 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/30-33,37\">",
"     30-33,37",
"    </a>",
"    ]. In uncontrolled series, long-term survival ranges from 10 to 40 percent, but local failure rates are between 32 and 55 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/31-33,37\">",
"     31-33,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with potentially resectable rectal cancer, lower local recurrence rates are reported using short course (five days) high-dose rate \"Swedish style\" of preoperative RT. However, this approach has not gained popularity in the United States, where preoperative chemoradiotherapy is preferred, if the patient can tolerate it. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is unlikely that sufficient downstaging would result from short-course, high-dose rate RT to allow a patient with a locally advanced initially unresectable rectal cancer to undergo successful resection. Conventional fluoropyrimidine-based chemoradiotherapy, which includes delivery of external beam RT in approximately 30 daily fractions over a six-week period to a dose of approximately 50 Gy is the preferred approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Preoperative chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for preoperative chemoradiotherapy for locally advanced rectal cancer is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with earlier stage resectable rectal cancer, postoperative (adjuvant) chemoradiotherapy provides a significant survival benefit when compared to surgery alone in the setting of transmural or node-positive disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4922?source=see_link\">",
"       \"Adjuvant therapy for resected rectal cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In this same population, a landmark randomized trial showed that preoperative as compared to postoperative chemoradiotherapy results in a superior sphincter preservation rate, a lower rate of anastomotic stenosis, and better local control, while providing similar long-term survival. These data are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link&amp;anchor=H12#H12\">",
"       \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\", section on 'Versus adjuvant chemoradiotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In retrospective series, preoperative chemoradiotherapy followed by surgery achieves high rates of local control (90 percent or better) and five-year overall survival rates of about 60 percent for patients with locally advanced",
"      <span class=\"nowrap\">",
"       (T3-4/node-positive)",
"      </span>",
"      rectal cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/2,38-42\">",
"       2,38-42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The superiority of preoperative chemoradiotherapy over preoperative radiotherapy alone for patients with locally advanced disease was shown in a randomized trial in which 207 patients with unresectable primary (n = 182) or locally recurrent (n = 25) rectal cancer were randomly assigned to RT (50 Gy) with or without 5-FU and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/43\">",
"     43",
"    </a>",
"    ]. Chemotherapy (bolus 5-FU alone) was administered concomitant with RT, and bolus 5-FU and leucovorin was given for 16 weeks after surgery as adjuvant chemotherapy.",
"   </p>",
"   <p>",
"    Among the statistically significant benefits for adding chemotherapy to RT were a higher complete (R0) resection rate (84 versus 68 percent), a higher pathologic complete response rate (16 versus 7 percent), and better five-year rates of local control (82 versus 67 percent), failure-free survival (63 versus 44 percent) and cancer-specific survival (72 versus 55 percent). Although grade 3 or 4 toxicity (mainly gastrointestinal) was significantly more common with chemoradiotherapy (29 versus 6 percent), late toxicity was not increased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Infusional versus bolus 5-FU",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the retrospective series and prospective uncontrolled trials that have explored preoperative chemoradiotherapy for locally advanced rectal cancer combine moderate to full dose RT (45 to 50.4 Gy) with a 5-FU-based chemotherapy regimen. Although the dose and techniques of RT are similar in most studies, there is marked variability in the chemotherapy regimen. In older studies, 5-FU was administered alone as a bolus for three consecutive days during weeks 1 and 5 of RT. The current preference for concomitant infusional 5-FU during RT by many institutions, including ours, is based upon an Intergroup study that demonstrated superiority of adjuvant concurrent infusional 5-FU compared to bolus 5-FU during RT in patients with resected rectal cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4922?source=see_link&amp;anchor=H8#H8\">",
"     \"Adjuvant therapy for resected rectal cancer\", section on 'Refinements in chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of infusional rather than bolus 5-FU may increase the likelihood of a pathologic complete response (pCR) in patients with locally advanced rectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/39\">",
"     39",
"    </a>",
"    ]. As has been seen in earlier stage disease, there is a correlation between the extent of the pathologic response to preoperative therapy and outcomes in patients treated for locally advanced rectal cancer. This was shown in a series of 77 patients with fixed or tethered T4 or recurrent rectal cancer treated with 5-FU-based chemotherapy (either bolus or infusional) and RT [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/44\">",
"     44",
"    </a>",
"    ]. At the time of surgery, 12 (16 percent) had a pCR, 10 (13 percent) had T1-2, N0 tumors, 31 percent had T3-4 N0, and 40 percent had node positive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/44\">",
"     44",
"    </a>",
"    ]. With a median follow-up of three years, the survival rate was 100 percent for T0-2, N0 cancers, compared with 80 percent for T3-4 N0 cancers and 73 percent for Tx N1-2 tumors (as staged according to the older 2002 AJCC TNM classification) (",
"    <a class=\"graphic graphic_table graphicRef56205 \" href=\"UTD.htm?19/20/19789\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Oral fluoropyrimidines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ease of administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    , and its demonstrated efficacy in the adjuvant setting of resected rectal cancer make it a particularly attractive alternative to infusional 5-FU. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4922?source=see_link&amp;anchor=H11#H11\">",
"     \"Adjuvant therapy for resected rectal cancer\", section on 'Orally active fluoropyrimidines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether orally active fluoropyrimidines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    ) represent an equally effective and well-tolerated replacement for infusional 5-FU during RT remains an unanswered question. Although uncontrolled studies are encouraging, randomized trials comparing this approach directly to infusional 5-FU concurrent with RT are needed before concluding that long-term outcomes are comparable. Such trials are underway. This topic is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link&amp;anchor=H19#H19\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\", section on 'Oral fluoropyrimidines versus infusional 5-FU'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Newer approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newer approaches to treatment include the incorporation of other drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    ),in combination with 5-FU or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    during chemoradiotherapy, combinations of infusional 5-FU with hyperfractionated (twice daily) RT, and the use of induction chemotherapy plus concomitant chemoradiotherapy. Early reports from trials using newer regimens are promising, but as with oral fluoropyrimidines, long-term results and trials directly comparing outcomes to those of infusional 5-FU concurrent with RT are not available. Some of these issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link&amp;anchor=H18#H18\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\", section on 'Choice of chemotherapy regimen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Intraoperative electron beam irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the use of full dose preoperative chemoradiotherapy and complete resection in patients with locally advanced rectal cancer, local failure occurs in at least one-third of patients. Rates are even higher in patients who cannot undergo complete resection following neoadjuvant therapy.",
"   </p>",
"   <p>",
"    At the Massachusetts General Hospital (MGH), Mayo Clinic, and other centers in the United States, Europe, and Asia, intraoperative electron beam RT (IORT) has been used in conjunction with preoperative irradiation (with and without 5-FU) and surgical resection when there is gross residual cancer, positive resection margins, or tumor adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/38,45-49\">",
"     38,45-49",
"    </a>",
"    ]. IORT is usually not given if, at the time of surgery, there is no tumor adherence and adequate soft tissue radial margins are present (&gt;1 cm).",
"   </p>",
"   <p>",
"    Typical IORT doses are in the range of 10 to 20 Gy. The IORT dose is usually 10 to 12.5 Gy in patients undergoing complete resection with negative margins, 12.5 to 15 Gy in patients undergoing subtotal resection with microscopic residual, and 17.5 to 20 Gy in patients with macroscopic tumor after resection.",
"   </p>",
"   <p>",
"    The benefit of this approach can be illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series from the MGH, 73 patients with locally advanced rectal cancer underwent full dose preoperative RT (with bolus 5-FU at the beginning and end of RT, in many cases) and followed by resection with IORT [",
"      <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/45\">",
"       45",
"      </a>",
"      ]. The five year actuarial rates of local control and disease-specific survival were dependent upon the type of surgical resection achieved:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Complete resection (R0) with IORT &mdash; 89 and 63 percent, respectively",
"     </li>",
"     <li>",
"      Partial resection with microscopic residual disease (R1) and IORT &mdash; 65 and 47 percent, respectively",
"     </li>",
"     <li>",
"      Partial resection with gross residual disease (R2) and IORT &mdash; 57 and 14 percent, respectively",
"      <br/>",
"      <br/>",
"      The five year actuarial risk of complications in the patients receiving IORT was 11 percent. Two patients developed osteoradionecrosis of the sacrum requiring surgical intervention. No deaths were seen as a consequence of these complications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At the Mayo Clinic, the treatment approach for primary locally advanced rectal cancer has been similar, combining preoperative external beam RT (with or without 5-FU) with surgery and IORT to high risk regions. One report detailed their experience in 146 patients with primary locally advanced colorectal cancer (106 rectal, the rest colon colon) who received conventional fractionation external beam RT (45 to 55 Gy) followed by surgery and IORT(10 to 20 Gy) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/46\">",
"       46",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The three- and five-year rates of freedom from local recurrence were 90 and 86 percent; disease-free survival rates for the entire group of patients were 52 and 43 percent at three and five years. Final surgical margins were negative in 100 patients, microscopically positive in 28, and grossly positive in 18. Patients with no or only microscopic residual disease had a higher rates of five-year disease-free (45 versus 26 percent) and overall survival (56 versus 22 percent) as compared to those with gross residual disease.",
"      <br/>",
"      <br/>",
"      There were 15 complications in 12 patients (8 percent) in the perioperative period. Long term complications occurred in 77 patients (53 percent), most commonly peripheral neuropathy (19 percent), bowel obstruction (14 percent) and ureteral obstruction (12 percent).",
"     </li>",
"     <li>",
"      Some series report the rate of sphincter preservation as an end point of therapy in patients with distal locally advanced rectal cancer. However, quality of life and functional outcome may be poorer for patients undergoing combined modality preoperative chemoradiotherapy, sphincter-preserving surgical resection, and IORT [",
"      <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When IORT is used, it is critical for the surgeon and radiation oncologist to define all high-risk areas to determine the optimal position for the IORT field. To direct the IORT, cones are used with internal diameters ranging from 4 to 8 cm; cone size is selected to fully cover the high-risk area, generally on the sacrum or pelvic sidewall. The cone must abut the site being treated, which can be difficult if the high-risk area is located in an anatomically confined region such as the pelvis. Most IORT treatments in rectal cancer are given through the abdomen but a perineal port is occasionally used to treat a very low-lying tumor involving the coccyx, distal pelvic side wall, or portions of the prostate and bladder when an exenteration is not performed. IORT can also be delivered by using HDR (high dose-rate) brachytherapy using a HAM applicator. An important point is that IORT should never be relied upon as a substitute for an adequate surgical procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Benefit of postoperative chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following resection of patients with rectal cancer who have received preoperative combined modality therapy, it is unclear, although most oncologists recommend it. The evidence used to support this approach is mainly an extrapolation of the proven benefit of postoperative adjuvant therapy with radiation and chemotherapy that was the standard of care in the era before preoperative combined modality therapy. Benefit from postoperative chemotherapy is also supported by some data from retrospective series of patients receiving preoperative chemoradiotherapy for rectal cancer as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link&amp;anchor=H27#H27\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\", section on 'Benefit of postoperative chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A retrospective analysis directly addressed the benefit of postsurgical chemotherapy in patients with locally advanced rectal cancer by comparing outcomes for three consecutive phase II studies in which the intensity of nonoperative therapy was gradually increased [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first protocol was entirely preoperative and consisted of concurrent RT and infusional 5-FU (30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day on days 1 to 4 and 15 to 18 of RT) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      C (8",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1).",
"     </li>",
"     <li>",
"      In the second protocol, RT was split between preoperative and postoperative, and concomitant 5-FU,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      was administered during both phases of RT, with one additional cycle of preoperative 5-FU and leucovorin.",
"     </li>",
"     <li>",
"      In the third protocol, the preoperative RT dose was increased to 50 Gy, administered with concurrent 5-FU and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      on days 1 through 4 and 22 to 25, and six cycles of postoperative adjuvant 5-FU and leucovorin were added.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When results from all three studies were compared, outcomes were best in the protocol that included six cycles of postoperative chemotherapy; five year survival increased from 52 to 84 percent, and relapse-free survival increased from 48 to 74 percent. Although this was not a randomized study, the results provide indirect support for postoperative chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modern treatment programs for locally advanced unresectable rectal cancer include the administration of concurrent chemotherapy with preoperative RT followed by resection with or without the use of IORT, and additional postoperative chemotherapy. At our institutions, all patients with locally advanced rectal cancer receive full dose preoperative RT with infusional 5-FU (225",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </span>",
"    five days per week) throughout the 5.5 to 6 week course of preoperative RT. The RT dose is 45 Gy to the pelvis followed by a tumor boost of 5.4 Gy in daily 1.8 Gy fractions. In our experience, this schedule has been well tolerated in conjunction with pelvic irradiation.",
"   </p>",
"   <p>",
"    Following neoadjuvant chemoradiotherapy, surgical exploration is undertaken four to eight weeks later. At surgery, the abdomen is carefully evaluated for liver and peritoneal metastases. If metastatic disease is excluded, the patients undergo abdominoperineal resection, low anterior resection, or pelvic exenteration depending upon the extent and location of the tumor. Attempts are made to resect as much disease as possible, even if some gross residual disease remains. The surgical specimen and the tumor bed are examined pathologically to define areas of possible residual disease, microscopic positive margins, or gross residual tumor. Patients who have any of these findings are considered for IORT.",
"   </p>",
"   <p>",
"    Following neoadjuvant chemoradiotherapy and surgery, additional postoperative chemotherapy is generally administered. Issues surrounding the choice of regimen are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link&amp;anchor=H18#H18\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\", section on 'Choice of chemotherapy regimen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     LOCALLY RECURRENT RECTAL CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of locally recurrent rectal cancer is a significant challenge. The choice of therapy depends upon prior therapy and the local extent of the recurrence. Since some of these patients have local recurrence alone without systemic spread of disease, local modalities such as surgery with or without radiation therapy (RT) may permit successful salvage. Local reirradiation alone may provide palliation, but has not been associated with long-term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/51\">",
"     51",
"    </a>",
"    ]. Other patients may achieve successful palliation with the use of an endoscopically placed, intraluminal self-expanding metal stent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5673?source=see_link\">",
"     \"Enteral stents for the management of malignant colorectal obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Surgical resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some cases may be amenable to surgical resection alone. Surgical resection may permit long-term survival in a subset of patients if they can be completely resected with negative margins [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/26,52-58\">",
"     26,52-58",
"    </a>",
"    ]. However, an extensive surgical procedure (eg, pelvic exenteration, partial sacrectomy) may be required. In addition to the potential for cure, these extensive procedures may improve both symptomatology and quality of life. However, these benefits must be weighed against the morbidity, the possibility of multiple permanent stomas, chronic pain, and even limited survival that results from aggressive surgery. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Exenterative procedures'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Contraindications for radical surgery include [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nerve root involvement above the level of L1-2",
"     </li>",
"     <li>",
"      Proximal (S1,2) sacral invasion extending to the sacral promontory &nbsp;",
"     </li>",
"     <li>",
"      Involvement of the paraaortic lymph nodes",
"     </li>",
"     <li>",
"      Tumor encasement of the iliac vessels",
"     </li>",
"     <li>",
"      Extension of tumor through the greater sciatic notch",
"     </li>",
"     <li>",
"      Bilateral ureteral obstruction",
"     </li>",
"     <li>",
"      Unresectable extrapelvic disease",
"     </li>",
"     <li>",
"      Circumferential involvement of the pelvic wall",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, these factors preclude a curative surgical procedure.",
"   </p>",
"   <p>",
"    Distant metastases (typically to liver or lung) may or may not be a relative contraindication depending on the location and potential for curative resection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=see_link\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Outcomes by histology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Together with the history and physical examination, preoperative imaging is one of the most important tools the surgeon has to select patients for these procedures. However, despite technical advances, preoperative imaging, particularly CT scan, tends to underestimate the extent of local infiltration and adjacent organ involvement by the tumor. The final decision for resectability is often made intraoperatively, with consideration for the location of the recurrence, and the presence of osseous, adjacent organ, vascular, lymphatic,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nerve root involvement.",
"   </p>",
"   <p>",
"    Although radical pelvic resection has traditionally been associated with the need for permanent fecal and urinary diversion, continence preservation may be feasible if an oncologically sound resection of the recurrent tumor can be carried out without impairing the integrity of the pelvic floor muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ideally, the management of these patients should be by an experienced multidisciplinary surgical team which may include, colorectal surgeons (or surgical oncologists), plastic and reconstructive surgeons, urologists, and neurosurgeons, among others.",
"   </p>",
"   <p>",
"    The outcomes of resection with or without postoperative therapy can be illustrated by a representative series of 90 patients with locally recurrent rectal or rectosigmoid cancer who underwent attempted resection for an isolated pelvic recurrence; 42 had received prior RT [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/55\">",
"     55",
"    </a>",
"    ]. The surgical procedure consisted of anterior resection, APR, exenteration, and local resections in 23,26,37, and 4 patients, respectively. The four local resections were composed of two perineal recurrences, one sacral resection, and one resection of an enlarged replaced internal iliac node.",
"   </p>",
"   <p>",
"    A negative resection margin was achieved in 51 (57 percent), and operative mortality was 4.4 percent. The perioperative complication rate was 53 percent, with infection being the most frequent complication (28 percent), followed by noninfectious wound complications (9.2 percent). Approximately one-half received additional chemotherapy after surgery for the recurrence, and 64 percent underwent RT. Five-year survival and disease-free survival rates were 40 and 32 percent, respectively. The local control rate was approximately 59 percent; failure patterns were local only in 15, distant in 16, and combined in 20 patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Combined modality therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of preoperative combined modality therapy for locally recurrent rectal cancer in previously unirradiated patients is supported by data from retrospective series [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/63-67\">",
"     63-67",
"    </a>",
"    ] and a randomized trial of chemoradiotherapy versus preoperative RT alone that included patients with locally recurrent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Preoperative chemoradiotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In the randomized trial, which is described above, a minority of enrolled patients (25 of 207) had locally recurrent rectal cancer; none had been previously irradiated. In the entire population, compared to preoperative radiotherapy alone, preoperative chemoradiotherapy was associated with a significantly higher complete (R0) resection rate (84 versus 68 percent) and pathologic complete response rate (16 versus 7 percent), as well as better five-year rates of local control (82 versus 67 percent), failure-free survival (63 versus 44 percent) and cancer-specific survival (72 versus 55 percent). Results were not stratified according to primary versus recurrent cancer. However, as a group, patients treated for locally recurrent cancer (n = 25) had a worse outcome than did those with primary disease (five-year failure-free and overall survival 30 and 37 percent, respectively). Furthermore, these patients were more likely to be categorically unresectable following preoperative therapy.",
"   </p>",
"   <p>",
"    Additional data on long-term prognosis come from a retrospective Mayo clinic series of 123 patients with previously unirradiated locally recurrent rectal cancer who were treated with a combination of external beam RT and concomitant 5-FU, maximal surgical resection, and IORT [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/63\">",
"     63",
"    </a>",
"    ]. The five-year local control rate was 63 percent, and overall survival at one, three and five years was 62, 39, and 20 percent, respectively.",
"   </p>",
"   <p>",
"    Prognostic factors were addressed in a series of 94 patients who received RT for previously unirradiated, locally recurrent rectal cancer; 63 also received chemotherapy, and 46 had resection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/64\">",
"     64",
"    </a>",
"    ]. At a median follow-up of 19 months, tumor recurred locally in 49 (52 percent) and with distant metastases in 57 (61 percent). For the entire cohort, survival rates at one, two, and three years were 74, 56, and 36 percent, respectively. In multivariate analysis, factors that were associated with a significantly greater likelihood of survival were better performance status, lower AJCC stage at recurrence, and higher hemoglobin levels during RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Intraoperative RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Favorable results are reported in series that utilize combined modality therapy that includes IORT administered at the time of surgical resection for locally recurrent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/68-70\">",
"     68-70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the use of IORT cannot compensate for incomplete resection in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/67,70,71\">",
"     67,70,71",
"    </a>",
"    ]. This was illustrated in series of 41 patients with locally recurrent rectal or rectosigmoid cancer who were treated with external beam RT, resection and IORT [",
"    <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/71\">",
"     71",
"    </a>",
"    ]. At five years, the local control and survival rates for patients undergoing complete surgical resection were 47 and 21 percent, respectively, while the corresponding values for those undergoing only subtotal resection were 21 and 7 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Previously irradiated patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic reirradiation is generally not undertaken for fear of prohibitive normal tissue complications. However, it is feasible in selected patients and may permit surgical salvage and long-term survival:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, 103 patients with locally recurrent rectal cancer following either preoperative or postoperative RT (median prior dose 50.4 Gy [range 30 to 74 Gy], median time to recurrence, 19 months) underwent reirradiation (median dose 34.8 Gy [range 15 to 49.2 Gy]), with concurrent 5-FU (200 to 300",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily by continuous infusion) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/72\">",
"       72",
"      </a>",
"      ]. Acute toxicities necessitated treatment interruption or termination in 22 percent of patients. Surgical resection of residual disease was undertaken in 34 patients, 14 of whom required pelvic exenteration; the remainder had RT alone. Although wound healing was slower, surgical morbidity was not dissimilar to patients treated without preoperative RT, and there was no operative mortality.",
"      <br/>",
"      <br/>",
"      At a median two-year follow-up, the median and actuarial five year survival rates were significantly higher for those undergoing surgery (44 months and 22 percent, respectively) compared to reirradiation alone (14 months and 15 percent, respectively). Late complications occurred in 22 patients and included persistent severe diarrhea in 18 (10 of whom required long-term parenteral support), small bowel obstruction in 15 (not related to tumor recurrence in four), fistula formation in four, and coloanal stricture in two.",
"     </li>",
"     <li>",
"      Similar results were noted in a retrospective study from the Netherlands of 147 patients with locally recurrent rectal cancer most of whom (n = 124) underwent preoperative combined modality treatment followed by extensive surgery and IORT; the remainder had surgery with or without postoperative adjuvant treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/67\">",
"       67",
"      </a>",
"      ]. Fifty seven (39 percent) had undergone prior pelvic irradiation, and their course of RT was limited to 30.6 Gy; other patients received 50.4 Gy.",
"      <br/>",
"      <br/>",
"      Patients who received either full course irradiation or reirradiation as a component of treatment survived significantly longer, and longer without local recurrence or metastases than did those who were not irradiated. However, the single most important factor in predicting survival after radical surgery and IORT for locally recurrent rectal cancer was a negative margin of resection. In the entire cohort, the five-year actuarial overall and cancer-specific survival rates were 32 and 39 percent, respectively. However, in patients with a microscopically complete (R0) resection, the actuarial five-year overall and cancer specific survival rates were 48 and 58 percent, respectively.",
"      <br/>",
"      <br/>",
"      Late complications were no more common in reirradiated patients than in previously unirradiated patients who underwent full-course preoperative chemoradiotherapy prior to surgery for recurrent disease.",
"     </li>",
"     <li>",
"      Long-term toxicity to normal tissues depends in part upon the size of each treatment fraction as well as the total radiation dose. Decreasing the size of each radiation fraction should permit higher total doses without increasing late morbidity. Hyperfractionation administers multiple daily treatments with smaller than conventional fraction sizes given over approximately the same treatment duration.",
"      <br/>",
"      <br/>",
"      The benefits of hyperfractionated RT in the setting of reirradiation were shown in a retrospective study of 50 patients who had prior pelvic irradiation and presented with either a primary (n = 2) or recurrent rectal cancer (n = 48) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/73\">",
"       73",
"      </a>",
"      ]. Retreatment consisted of 1.5 Gy fractions twice daily to a total dose of 30 Gy if the retreatment interval was less than one year, and to total dose of 39 Gy if the retreatment interval was over one year. Concomitant chemotherapy was administered to 96 percent of the patients, and 18 underwent surgical resection after retreatment.",
"      <br/>",
"      <br/>",
"      The three-year overall survival was 66 percent for those patients who underwent surgical resection, and 27 percent for those who did not. At three years, the rate of grade 3 and 4 late toxicity was 35 percent.",
"      <br/>",
"      <br/>",
"      Similar results have been shown by others using hyperfractionated reirradiation with concurrent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/37/11866/abstract/74\">",
"       74",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     PALLIATION OF OBSTRUCTIVE SYMPTOMS DUE TO LOCALLY ADVANCED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients who present with locally unresectable or metastatic rectal cancer, the goal of surgery is relief of obstruction rather than cure. Although symptom relief can often be achieved through bowel bypass, endoscopic laser ablation, or stent placement, palliative tumor resection is often performed. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/29/19930?source=see_link\">",
"     \"Locoregional methods for management and palliation in patients who present with stage IV colorectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5673?source=see_link\">",
"     \"Enteral stents for the management of malignant colorectal obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/0/6148?source=see_link\">",
"       \"Patient information: Colon and rectal cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/22/40293?source=see_link\">",
"       \"Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A locally advanced unresectable rectal cancer is defined as one that cannot be resected without a high likelihood of leaving microscopic or gross residual disease at the local site because of tumor adherence or fixation to that site. Most of these are fixed cancers that directly invade adjacent structures or organs and cannot be resected with negative margins (a T4 lesion) (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition to a digital clinical examination (which may require an examination under anesthesia), the preoperative evaluation for patients with a locally advanced or recurrent rectal cancer should include both CT and thin-cut MRI with a pelvic phased-array coil. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pretreatment evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Treatment of locally advanced unresectable disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following reflects our general approach to management of patients with locally advanced, unresectable but nonmetastatic rectal cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend combined modality therapy over radiation therapy (RT) alone for patients who are able to tolerate it. (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Combinations of moderate to high-dose preoperative RT with concurrent 5-FU based chemotherapy result in improved rates of resectability, local control, and survival. At our institutions, all patients with locally advanced rectal cancer receive full-dose preoperative RT with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      (825",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       /day",
"      </span>",
"      five days per week) or infusional 5-FU (225",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       /day",
"      </span>",
"      five days per week) throughout the five and one half week course of preoperative RT (45 Gy to the pelvis followed by a tumor boost of 5.4 Gy).",
"     </li>",
"     <li>",
"      Following neoadjuvant chemoradiotherapy, surgical exploration is undertaken six to eight weeks later. At surgery, the abdomen is carefully evaluated for liver and peritoneal metastases. If metastatic disease is excluded and the tumor is resectable, the patient undergoes abdominoperineal resection, low anterior resection, or pelvic exenteration depending upon the extent and location of the tumor. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'General surgical principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At institutions where it is available, intraoperative electron beam RT (IORT) may be used in conjunction with preoperative chemoradiotherapy and surgical resection when there is gross residual cancer, positive resection margins, or tumor adherence. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Intraoperative electron beam irradiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following surgery, we suggest additional postoperative chemotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The optimal regimen has not been established. Options include 5-fluorouracil plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      alone, or an",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -based regimen. At our institutions, most patients receive an oxaliplatin-based regimen such as FOLFOX, as is used for adjuvant treatment of node-positive colon cancer (",
"      <a class=\"graphic graphic_table graphicRef50132 \" href=\"UTD.htm?16/53/17246\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link&amp;anchor=H28#H28\">",
"       \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\", section on 'Choice of postoperative regimen'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Management of locally recurrent rectal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of a locally recurrent rectal cancer is a significant challenge. The choice of therapy depends upon prior therapy, and the local extent of the recurrence.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some cases of isolated locoregional recurrence may be amenable to surgical resection alone. However, an extensive operative procedure (eg, pelvic exenteration) may be required to achieve negative margins. For patients who have not received prior RT, we recommend combined modality therapy rather than surgery alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Combined modality therapy'",
"      </a>",
"      above.) Our recommended approach is the same as for locally advanced unresectable primary tumors, outlined above. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment of locally advanced disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For previously irradiated patients, pelvic reirradiation is feasible in selected patients and may permit surgical salvage and long-term survival. The dose of RT for reirradiation in this setting should be limited to 30 to 39 Gy. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Previously irradiated patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/2\">",
"      Guillem JG, Chessin DB, Cohen AM, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg 2005; 241:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/3\">",
"      Farouk R, Nelson H, Radice E, et al. Accuracy of computed tomography in determining resectability for locally advanced primary or recurrent colorectal cancers. Am J Surg 1998; 175:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/4\">",
"      Beets-Tan RG, Beets GL, Borstlap AC, et al. Preoperative assessment of local tumor extent in advanced rectal cancer: CT or high-resolution MRI? Abdom Imaging 2000; 25:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/5\">",
"      Dresen RC, Kusters M, Daniels-Gooszen AW, et al. Absence of tumor invasion into pelvic structures in locally recurrent rectal cancer: prediction with preoperative MR imaging. Radiology 2010; 256:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/6\">",
"      Messiou C, Chalmers AG, Boyle K, et al. Pre-operative MR assessment of recurrent rectal cancer. Br J Radiol 2008; 81:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/7\">",
"      Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001; 93:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/8\">",
"      McGory ML, Shekelle PG, Ko CY. Development of quality indicators for patients undergoing colorectal cancer surgery. J Natl Cancer Inst 2006; 98:1623.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/10\">",
"      Tjandra JJ, Kilkenny JW, Buie WD, et al. Practice parameters for the management of rectal cancer (revised). Dis Colon Rectum 2005; 48:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/11\">",
"      Lopez MJ. Multivisceral resections for colorectal cancer. J Surg Oncol 2001; 76:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/12\">",
"      Nakafusa Y, Tanaka T, Tanaka M, et al. Comparison of multivisceral resection and standard operation for locally advanced colorectal cancer: analysis of prognostic factors for short-term and long-term outcome. Dis Colon Rectum 2004; 47:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/13\">",
"      Rowe VL, Frost DB, Huang S. Extended resection for locally advanced colorectal carcinoma. Ann Surg Oncol 1997; 4:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/14\">",
"      Lehnert T, Methner M, Pollok A, et al. Multivisceral resection for locally advanced primary colon and rectal cancer: an analysis of prognostic factors in 201 patients. Ann Surg 2002; 235:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/15\">",
"      Luna-P&eacute;rez P, Rodr&iacute;guez-Ram&iacute;rez SE, De la Barrera MG, et al. Multivisceral resection for colon cancer. J Surg Oncol 2002; 80:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/16\">",
"      Poeze M, Houbiers JG, van de Velde CJ, et al. Radical resection of locally advanced colorectal cancer. Br J Surg 1995; 82:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/17\">",
"      Govindarajan A, Coburn NG, Kiss A, et al. Population-based assessment of the surgical management of locally advanced colorectal cancer. J Natl Cancer Inst 2006; 98:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/18\">",
"      Pawlik TM, Skibber JM, Rodriguez-Bigas MA. Pelvic exenteration for advanced pelvic malignancies. Ann Surg Oncol 2006; 13:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/19\">",
"      Balbay MD, Slaton JW, Trane N, et al. Rationale for bladder-sparing surgery in patients with locally advanced colorectal carcinoma. Cancer 1999; 86:2212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/20\">",
"      Law WL, Chu KW, Choi HK. Total pelvic exenteration for locally advanced rectal cancer. J Am Coll Surg 2000; 190:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/21\">",
"      Hafner GH, Herrera L, Petrelli NJ. Morbidity and mortality after pelvic exenteration for colorectal adenocarcinoma. Ann Surg 1992; 215:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/22\">",
"      Palmer G, Martling A, Lagergren P, et al. Quality of life after potentially curative treatment for locally advanced rectal cancer. Ann Surg Oncol 2008; 15:3109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/23\">",
"      Kakuda JT, Lamont JP, Chu DZ, Paz IB. The role of pelvic exenteration in the management of recurrent rectal cancer. Am J Surg 2003; 186:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/24\">",
"      Akasu T, Yamaguchi T, Fujimoto Y, et al. Abdominal sacral resection for posterior pelvic recurrence of rectal carcinoma: analyses of prognostic factors and recurrence patterns. Ann Surg Oncol 2007; 14:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/25\">",
"      Gannon CJ, Zager JS, Chang GJ, et al. Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma. Ann Surg Oncol 2007; 14:1870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/26\">",
"      Sagar PM, Gonsalves S, Heath RM, et al. Composite abdominosacral resection for recurrent rectal cancer. Br J Surg 2009; 96:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/27\">",
"      WANG CC, SCHULZ MD. The role of radiation therapy in the management of carcinoma of the sigmoid, rectosigmoid, and rectum. Radiology 1962; 79:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/28\">",
"      O'Connell MJ, Childs DS, Moertel CG, et al. A prospective controlled evaluation of combined pelvic radiotherapy and methanol extraction residue of BCG (MER) for locally unresectable or recurrent rectal carcinoma. Int J Radiat Oncol Biol Phys 1982; 8:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/29\">",
"      Brierley JD, Cummings BJ, Wong CS, et al. Adenocarcinoma of the rectum treated by radical external radiation therapy. Int J Radiat Oncol Biol Phys 1995; 31:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/30\">",
"      Emami B, Pilepich M, Willett C, et al. Effect of preoperative irradiation on resectability of colorectal carcinomas. Int J Radiat Oncol Biol Phys 1982; 8:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/31\">",
"      Dosoretz DE, Gunderson LL, Hedberg S, et al. Preoperative irradiation for unresectable rectal and rectosigmoid carcinomas. Cancer 1983; 52:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/32\">",
"      Mendenhall WM, Million RR, Bland KI, et al. Initially unresectable rectal adenocarcinoma treated with preoperative irradiation and surgery. Ann Surg 1987; 205:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/33\">",
"      Stevens KR, Fletcher WS. High dose preoperative pelvic irradiation for unresectable adenocarcinoma of the rectum or sigmoid. Int J Radiat Oncol Biol Phys 1983; 9:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/34\">",
"      Allee PE, Tepper JE, Gunderson LL, Munzenrider JE. Postoperative radiation therapy for incompletely resected colorectal carcinoma. Int J Radiat Oncol Biol Phys 1989; 17:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/35\">",
"      Schild SE, Martenson JA Jr, Gunderson LL, Dozois RR. Long-term survival and patterns of failure after postoperative radiation therapy for subtotally resected rectal adenocarcinoma. Int J Radiat Oncol Biol Phys 1989; 16:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/36\">",
"      Ghossein NA, Samala EC, Alpert S, et al. Elective postoperative radiotherapy after incomplete resection of colorectal cancer. Dis Colon Rectum 1981; 24:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/37\">",
"      Whiting JF, Howes A, Osteen RT. Preoperative irradiation for unresectable carcinoma of the rectum. Surg Gynecol Obstet 1993; 176:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/38\">",
"      Valentini V, Coco C, Rizzo G, et al. Outcomes of clinical T4M0 extra-peritoneal rectal cancer treated with preoperative radiochemotherapy and surgery: a prospective evaluation of a single institutional experience. Surgery 2009; 145:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/39\">",
"      Mohiuddin M, Regine WF, John WJ, et al. Preoperative chemoradiation in fixed distal rectal cancer: dose time factors for pathological complete response. Int J Radiat Oncol Biol Phys 2000; 46:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/40\">",
"      Chan AK, Wong AO, Langevin J, et al. Preoperative chemotherapy and pelvic radiation for tethered or fixed rectal cancer: a phase II dose escalation study. Int J Radiat Oncol Biol Phys 2000; 48:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/41\">",
"      Janjan NA, Khoo VS, Abbruzzese J, et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 1999; 44:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/42\">",
"      Videtic GM, Fisher BJ, Perera FE, et al. Preoperative radiation with concurrent 5-fluorouracil continuous infusion for locally advanced unresectable rectal cancer. Int J Radiat Oncol Biol Phys 1998; 42:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/43\">",
"      Braendengen M, Tveit KM, Berglund A, et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 2008; 26:3687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/44\">",
"      Mohiuddin M, Hayne M, Regine WF, et al. Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J Radiat Oncol Biol Phys 2000; 48:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/45\">",
"      Nakfoor BM, Willett CG, Shellito PC, et al. The impact of 5-fluorouracil and intraoperative electron beam radiation therapy on the outcome of patients with locally advanced primary rectal and rectosigmoid cancer. Ann Surg 1998; 228:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/46\">",
"      Mathis KL, Nelson H, Pemberton JH, et al. Unresectable colorectal cancer can be cured with multimodality therapy. Ann Surg 2008; 248:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/47\">",
"      Kim HK, Jessup JM, Beard CJ, et al. Locally advanced rectal carcinoma: pelvic control and morbidity following preoperative radiation therapy, resection, and intraoperative radiation therapy. Int J Radiat Oncol Biol Phys 1997; 38:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/48\">",
"      Roeder F, Treiber M, Oertel S, et al. Patterns of failure and local control after intraoperative electron boost radiotherapy to the presacral space in combination with total mesorectal excision in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2007; 67:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/49\">",
"      Kusters M, Holman FA, Martijn H, et al. Patterns of local recurrence in locally advanced rectal cancer after intra-operative radiotherapy containing multimodality treatment. Radiother Oncol 2009; 92:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/50\">",
"      Shibata D, Guillem JG, Lanouette N, et al. Functional and quality-of-life outcomes in patients with rectal cancer after combined modality therapy, intraoperative radiation therapy, and sphincter preservation. Dis Colon Rectum 2000; 43:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/51\">",
"      Lingareddy V, Ahmad NR, Mohiuddin M. Palliative reirradiation for recurrent rectal cancer. Int J Radiat Oncol Biol Phys 1997; 38:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/52\">",
"      Hansen MH, Balteskard L, D&oslash;rum LM, et al. Locally recurrent rectal cancer in Norway. Br J Surg 2009; 96:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/53\">",
"      Garcia-Aguilar J, Cromwell JW, Marra C, et al. Treatment of locally recurrent rectal cancer. Dis Colon Rectum 2001; 44:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/54\">",
"      Tepper JE, O'Connell M, Hollis D, et al. Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114. J Clin Oncol 2003; 21:3623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/55\">",
"      Henry LR, Sigurdson E, Ross EA, et al. Resection of isolated pelvic recurrences after colorectal surgery: long-term results and predictors of improved clinical outcome. Ann Surg Oncol 2007; 14:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/56\">",
"      Ferenschild FT, Vermaas M, Verhoef C, et al. Abdominosacral resection for locally advanced and recurrent rectal cancer. Br J Surg 2009; 96:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/57\">",
"      Bhangu A, Brown G, Akmal M, Tekkis P. Outcome of abdominosacral resection for locally advanced primary and recurrent rectal cancer. Br J Surg 2012; 99:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/58\">",
"      Colibaseanu DT, Mathis KL, Abdelsatter ZM, et al. Is curative resection and long-term survival possible for locally re-recurrent colorectal cancer in the pelvis? Dis Colon Rectum 2013; 56:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/59\">",
"      Bouchard P, Efron J. Management of recurrent rectal cancer. Ann Surg Oncol 2010; 17:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/60\">",
"      Moore HG, Shoup M, Riedel E, et al. Colorectal cancer pelvic recurrences: determinants of resectability. Dis Colon Rectum 2004; 47:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/61\">",
"      Wasserberg N, Kaiser AM, Nunoo-Mensah JW, et al. Preservation of bowel and urinary continence in the management of locally recurrent rectal cancer. J Surg Oncol 2005; 92:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/62\">",
"      Koda K, Tobe T, Takiguchi N, et al. Pelvic exenteration for advanced colorectal cancer with reconstruction of urinary and sphincter functions. Br J Surg 2002; 89:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/63\">",
"      Gunderson LL, Nelson H, Martenson JA, et al. Intraoperative electron and external beam irradiation with or without 5-fluorouracil and maximum surgical resection for previously unirradiated, locally recurrent colorectal cancer. Dis Colon Rectum 1996; 39:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/64\">",
"      Rades D, Kuhn H, Schultze J, et al. Prognostic factors affecting locally recurrent rectal cancer and clinical significance of hemoglobin. Int J Radiat Oncol Biol Phys 2008; 70:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/65\">",
"      R&ouml;del C, Grabenbauer GG, Matzel KE, et al. Extensive surgery after high-dose preoperative chemoradiotherapy for locally advanced recurrent rectal cancer. Dis Colon Rectum 2000; 43:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/66\">",
"      Stocchi L, Nelson H, Sargent DJ, et al. Is en-bloc resection of locally recurrent rectal carcinoma involving the urinary tract indicated? Ann Surg Oncol 2006; 13:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/67\">",
"      Dresen RC, Gosens MJ, Martijn H, et al. Radical resection after IORT-containing multimodality treatment is the most important determinant for outcome in patients treated for locally recurrent rectal cancer. Ann Surg Oncol 2008; 15:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/68\">",
"      Alektiar KM, Zelefsky MJ, Paty PB, et al. High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer. Int J Radiat Oncol Biol Phys 2000; 48:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/69\">",
"      Mannaerts GH, Martijn H, Crommelin MA, et al. Intraoperative electron beam radiation therapy for locally recurrent rectal carcinoma. Int J Radiat Oncol Biol Phys 1999; 45:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/70\">",
"      Haddock MG, Miller RC, Nelson H, et al. Combined modality therapy including intraoperative electron irradiation for locally recurrent colorectal cancer. Int J Radiat Oncol Biol Phys 2011; 79:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/71\">",
"      Wallace HJ 3rd, Willett CG, Shellito PC, et al. Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer. J Surg Oncol 1995; 60:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/72\">",
"      Mohiuddin M, Marks G, Marks J. Long-term results of reirradiation for patients with recurrent rectal carcinoma. Cancer 2002; 95:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/73\">",
"      Das P, Delclos ME, Skibber JM, et al. Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation. Int J Radiat Oncol Biol Phys 2010; 77:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/37/11866/abstract/74\">",
"      Sun DS, Zhang JD, Li L, et al. Accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer. Br J Radiol 2012; 85:259.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2528 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-200.215.4.194-785DB895A1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_37_11866=[""].join("\n");
var outline_f11_37_11866=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Definition of locally advanced disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Physical and endoscopic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GENERAL SURGICAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Exenterative procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT OF LOCALLY ADVANCED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RT alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      External beam RT and surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Postoperative RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Preoperative RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Preoperative chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Infusional versus bolus 5-FU",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Oral fluoropyrimidines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Newer approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Intraoperative electron beam irradiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Benefit of postoperative chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      LOCALLY RECURRENT RECTAL CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Surgical resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Combined modality therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Intraoperative RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Previously irradiated patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PALLIATION OF OBSTRUCTIVE SYMPTOMS DUE TO LOCALLY ADVANCED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Treatment of locally advanced unresectable disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Management of locally recurrent rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2528\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2528|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/26/23982\" title=\"table 1\">",
"      2010 TNM staging colorectal CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/20/19789\" title=\"table 2\">",
"      2002 AJCC staging CRC CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/53/17246\" title=\"table 3\">",
"      Modified FOLFOX6",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4922?source=related_link\">",
"      Adjuvant therapy for resected rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17946?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5673?source=related_link\">",
"      Enteral stents for the management of malignant colorectal obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/29/19930?source=related_link\">",
"      Locoregional methods for management and palliation in patients who present with stage IV colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=related_link\">",
"      Management of potentially resectable colorectal cancer liver metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=related_link\">",
"      Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/0/6148?source=related_link\">",
"      Patient information: Colon and rectal cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/22/40293?source=related_link\">",
"      Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6041?source=related_link\">",
"      Pretreatment local staging evaluation for rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=related_link\">",
"      Surgical resection of pulmonary metastases: Outcomes by histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28634?source=related_link\">",
"      Surveillance after colorectal cancer resection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_37_11867="LD definition Natl Joint Comm";
var content_f11_37_11867=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    National Joint Committee on Learning Disabilities definition of learning disabilities, 1994",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        \"Learning Disabilities is a generic term that refers to",
"a heterogeneous group of disorders manifested by significant",
"difficulties in the acquisition and use of listening, speaking,",
"reading, writing, reasoning, or mathematical abilities. These disorders",
"are intrinsic to the individual and presumed to be due to central",
"nervous system dysfunction. Even though a learning disability may occur",
"concomitantly with other handicapping conditions (eg, sensory",
"impairment, mental retardation, social and emotional disturbance) or",
"environmental influences (eg, cultural differences, insufficient or",
"inappropriate instruction, psychogenic factors), it is not the direct",
"result of those conditions or influences.\"",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     American Speech-Language Hearing Association; Association for Children and Adults with Learning Disabilities; Council for Learning Disabilities; Division for Children with Communication Disorders, Council for Exceptional Children; Division for Learning Disabilities, Council for Exceptional Children; International Reading Association; National Association for School Psychologists; The Orton Dyslexia Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_37_11867=[""].join("\n");
var outline_f11_37_11867=null;
var title_f11_37_11868="Temporary transvenous pacing indications";
var content_f11_37_11868=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for temporary transvenous pacing*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Asystole.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Symptomatic bradycardia (includes sinus bradycardia with hypotension and type I second-degree AV block with hypotension not responsive to atropine).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Bilateral BBB (alternating BBB, or RBBB with alternating LAFB/LPFB) (any age).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. New or indeterminate age bifascicular block (RBBB with LAFB or LPFB, or LBBB).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Mobitz type II second-degree AV block.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. RBBB and LAFB or LPFB (new or indeterminate).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. RBBB with first-degree AV block.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. LBBB, new or indeterminate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Incessant VT, for atrial or ventricular overdrive pacing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Recurrent sinus pauses (greater than 3 seconds) not responsive to atropine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Bifascicular block of indeterminate age.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. New or age-indeterminate isolated RBBB.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. First-degree heart block.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Type I second-degree AV block with normal hemodynamics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Accelerated idioventricular rhythm.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Bundle branch block known to exist before acute MI.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * It should be noted that in choosing a transvenous pacemaker system, patients with substantially depressed ventricular performance, including RV infarction, may respond better to atrial/AV sequential pacing than ventricular pacing.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Ryan, TJ, Anderson, JL, Antman, EM, et al, JACC 1996; 28:1367-1368.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_37_11868=[""].join("\n");
var outline_f11_37_11868=null;
var title_f11_37_11869="BARC definition for bleeding";
var content_f11_37_11869=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Bleeding Academic Research Consortium definition for bleeding",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Type 0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Type 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bleeding that is not actionable and does not cause the patient to seek unscheduled performance of studies, hospitalization, or treatment by a healthcare professional; may include episodes leading to self-discontinuation of medical therapy by the patient without consulting a healthcare professional",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Type 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any overt, actionable sign of hemorrhage (eg, more bleeding than would be expected for a clinical circumstance, including bleeding found by imaging alone) that does not fit the criteria for type 3, 4, or 5 but does meet at least one of the following criteria: (1) requiring nonsurgical, medical intervention by a healthcare professional, (2) leading to hospitalization or increased level of care, or (3) prompting evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Type 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Type 3a",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Overt bleeding plus hemoglobin drop of 3 to &lt;5 g/dL* (provided hemoglobin drop is related to bleed)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Any transfusion with overt bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Type 3b",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Overt bleeding plus hemoglobin drop &ge;5 g/dL* (provided hemoglobin drop is related to bleed)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cardiac tamponade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bleeding requiring intravenous vasoactive agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Type 3c",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation, does include intraspinal)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Subcategories confirmed by autopsy or imaging or lumbar puncture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intraocular bleed compromising vision",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Type 4: CABG-related bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perioperative intracranial bleeding within 48 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reoperation after closure of sternotomy for the purpose of controlling bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transfusion of &ge;5 U whole blood or packed red blood cells within a 48-h period",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest tube output &ge;2 L within a 24-h period",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Type 5: Fatal bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Type 5a",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Type 5b",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    CABG indicates coronary artery bypass graft. Platelet tranfusions should be recorded and reported but are not included in these definitions until further information is obtatined about the relationship to oucomes. If a CABG-related bleed is not adjudicated as at least a type 3 severity event, it will be classified as not a bleeding event. If a bleeding event occurs with a clear temporal relationship to CABG (ie, within a 48-h time frame) but does not meet type 4 severity criteria, it will be classified as not a bleeding event.",
"    <div class=\"footnotes\">",
"     CABG: coronary artery bypass graft.",
"     <br>",
"      * Corrected for transfusion (1 U packed red blood cells or 1 U whole blood = 1 g/dL hemoglobin).",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Cell saver products are not counted.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123:2736. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_37_11869=[""].join("\n");
var outline_f11_37_11869=null;
var title_f11_37_11870="Fat distribution and NIDDM";
var content_f11_37_11870=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F56394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F56394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Obesity and fat distribution impair glucose tolerance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 247px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Serial changes in blood glucose concentrations during an oral glucose tolerance test in nine patients with upper body obesity, 16 patients with lower body obesity, and nine normal subjects. Both obese groups had impaired glucose tolerance, but the abnormality was more pronounced in the group with upper body obesity. The degree of glucose intolerance underestimated the degree of insulin resistance since peak serum insulin concentrations were also much higher in the group with upper body obesity (225 &micro;U/mL versus 115 and 65 &micro;U/mL in the other two groups). To convert blood glucose to mmol/L, divide by 18; to convert serum insulin to pmol/L, multiply by 6.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Kissebah, A, Vydelingum, N, Murray, R, et al, J Clin Endocrinol Metab 1982; 54:254.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_37_11870=[""].join("\n");
var outline_f11_37_11870=null;
var title_f11_37_11871="Duodenal ulcer Endosc";
var content_f11_37_11871=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Duodenal ulcer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy shows a discrete ulcer in the duodenal bulb. This benign ulcer has a flat, smooth ulcer base that is filled with exudate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_37_11871=[""].join("\n");
var outline_f11_37_11871=null;
